MIRNAs predict response to cancer treatment

JP2024521124A5Pending Publication Date: 2024-11-08HUMMINGBIRD DIAGNOSTICS GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023572035
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-09-13
Filing Date
2022-04-13
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Current cancer treatment methods, particularly immunotherapy, lack accurate biomarkers for predicting patient response and survival, leading to uncertainty in treatment choices and potential severe side effects.

Method used

Identification of specific microRNA (miRNA) biomarkers in peripheral blood samples, which can predict response to cancer treatment, including immunotherapy, and provide survival prognosis by determining their levels in patients with cancer.

Benefits of technology

Enables rapid and accurate clinical prediction of treatment response and survival prognosis, allowing for personalized treatment decisions and reducing the need for invasive biopsies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000099_0000
    Figure 00000099_0000
  • Figure 00000099_0001
    Figure 00000099_0001
  • Figure 00000100_0000
    Figure 00000100_0000
Patent Text Reader

Abstract

The present invention relates to a method for predicting the response of a patient suffering from cancer. Further, the present invention relates to a method for providing a prognosis for a patient suffering from cancer. Further, the present invention relates to a method for deciding whether to treat a patient suffering from cancer. Further, the present invention relates to a method for selecting a patient suffering from cancer who will benefit from immunochemotherapy or immunotherapy. Furthermore, the present invention relates to a kit for carrying out these methods.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for predicting the response of a patient suffering from cancer to a cancer treatment. Further, the present invention relates to a method for providing a prognosis for a patient suffering from cancer. Further, the present invention relates to a method for deciding whether to treat a patient suffering from cancer. Further, the present invention relates to a method for selecting a patient suffering from cancer who will benefit from immunochemotherapy or immunotherapy. Furthermore, the present invention relates to a kit for carrying out these methods. [Background technology]

[0002] Cancer is the uncontrolled growth of abnormal cells somewhere in the body. The abnormal cells are called cancer cells, malignant cells, or tumor cells. Cancer cells may grow out of control and form a mass of cancer cells.

[0003] Cancer treatments include, but are not limited to, immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, antihormonal therapy, immunosuppressive therapy, antibody therapy, and surgical therapy. Standard clinical parameters such as tumor size, grade, lymph node metastasis, and tumor-node-metastasis (TNM) staging may correlate with outcome and severity to stratify patients for cancer treatment regimens. However, stage-matched tumors grouped by histological subtypes may respond differently to the same treatment regimen.

[0004] Immunotherapy has recently been recognized as a highly effective treatment in advanced cancer. The drugs used in immunotherapy work by blocking mechanisms that tumors typically evade detection and unlocking the immune system to fight cancer. In addition to significant benefits, immunotherapy can be accompanied by characteristic (and sometimes severe) side effects. For this reason, immunotherapy should be administered only to patients in whom the benefits are predicted to outweigh the risks. Central to predicting response to immunotherapy in the PD-1 inhibitor class (nivolumab and pembrolizumab) is the quantification of tumor PD-L1 expression. However, still only about 30% of patients achieve a positive response.

[0005] Furthermore, in advanced cancer, immunotherapy (IO) alone or in combination with chemotherapy (i.e., immunochemotherapy (ICT)) is recommended as a treatment option in major international guidelines, but there is still uncertainty regarding the ideal treatment choice for individual patients.

[0006] Positive responses to immunotherapy depend on both local interactions between malignant and immune cells in the tumor microenvironment and more distal interactions between tumors and the peripheral immune system. The latter may provide non-invasive therapeutic guidance, but blood-based biomarkers have not yet entered routine clinical use.

[0007] Therefore, there is an urgent need for more accurate biomarkers for cancer treatment, especially immunotherapy, response prediction, and survival prediction. Furthermore, there is an urgent need for new biomarkers that can identify patients who will benefit from chemotherapy in addition to immunotherapy.

[0008] Several lines of evidence suggest that information retained in peripheral blood may predict immune responses within the local tumor microenvironment. Correlations have been found between immunotherapy response and peripheral blood counts and peripherally expanded T cell clones.

[0009] The present inventors have identified response and survival predictive miRNAs from whole blood for cancer therapy, particularly immunotherapy. These new miRNAs allow rapid and accurate clinical response prediction and life prognosis in cancer disease. Thus, said miRNAs can be used as companion or complementary diagnostics in cancer therapy, particularly immunotherapy. As an additional advantage, repeated liquid biopsies are more feasible than serial tumor biopsies (as required by prior art methods) to reduce procedural risks, perform longitudinal monitoring, and as a means to investigate the dynamic process of, for example, tumor PD-L1 expression. Furthermore, these new miRNAs allow the selection of patients suffering from cancer to benefit from immunochemotherapy or immunotherapy. Summary of the Invention

[0010] In a first aspect, the present invention relates to a method for predicting response to cancer treatment in a patient suffering from cancer, comprising determining the level of at least one miRNA in a blood sample of the patient suffering from cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 44, fragments thereof and sequences having at least 80% sequence identity thereto.

[0011] In a second aspect, the present invention relates to a method for providing a prognosis to a patient suffering from cancer, comprising determining the level of at least one miRNA in a blood sample of the patient suffering from cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80% sequence identity thereto.

[0012] In a third aspect, the present invention relates to a method for predicting side effects of cancer treatment in a patient, comprising determining the level of at least one miRNA in a blood sample of a patient suffering from cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80% sequence identity thereto.

[0013] In a fourth aspect, the present invention relates to a method for monitoring a patient suffering from cancer, comprising determining the level of at least one miRNA in a blood sample of the patient suffering from cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof and sequences having at least 80% sequence identity thereto.

[0014] In a fifth aspect, the present invention provides a method for producing a composition comprising the steps of: (i) identifying a patient who responds to cancer treatment by carrying out the method according to the first aspect, identifying a patient with a good prognosis by carrying out the method according to the second aspect, or identifying a patient who does not experience side effects from cancer treatment by carrying out the method according to the third aspect; (ii) allocating the patient to a cancer treatment (as defined above); The present invention relates to a method for determining whether to treat a patient suffering from cancer, comprising:

[0015] In a sixth aspect, the present invention relates to the use of at least one miRNA for predicting the response of a patient suffering from cancer to a cancer treatment, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80% sequence identity thereto.

[0016] In a seventh aspect, the present invention relates to the use of at least one miRNA for providing a prognosis to a patient suffering from cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80% sequence identity thereto.

[0017] In an eighth aspect, the present invention relates to the use of at least one miRNA for predicting side effects in cancer treatment in a patient, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80% sequence identity thereto.

[0018] In a ninth aspect, the present invention relates to the use of at least one miRNA for monitoring a patient suffering from cancer, wherein said at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof and sequences having at least 80% sequence identity thereto.

[0019] In a tenth aspect, the present invention relates to the use of at least one miRNA for determining whether to treat a patient suffering from cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80% sequence identity thereto.

[0020] In an eleventh aspect, the present invention relates to a kit for predicting a response of a patient suffering from cancer to a cancer treatment, for providing a prognosis for a patient suffering from cancer, for predicting side effects in a patient's cancer treatment, for monitoring a patient suffering from cancer, or for deciding whether to treat a patient suffering from cancer, wherein the kit comprises a means for determining the expression level of at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80% sequence identity thereto.

[0021] In a twelfth aspect, the present invention relates to a method for selecting a patient suffering from cancer to benefit from immunochemotherapy or immunotherapy, comprising determining the level of at least one miRNA in a blood sample of said patient, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 (miR-2115-3p), SEQ ID NO:39 (miR-218-5p), SEQ ID NO:13 (miR-224-5p), SEQ ID NO:7 (miR-4676-3p), SEQ ID NO:34 (miR-6503-5p), fragments thereof, and sequences having at least 80% sequence identity thereto, and wherein the patient optionally has a PD-L1 Tumor Proportion Score (TPS) of ≧50%.

[0022] In a thirteenth aspect, the present invention provides a method for producing a composition comprising the steps of: (i) identifying a patient who will benefit from immunochemotherapy or immunotherapy by carrying out the method according to the twelfth aspect; and (ii) assigning the patient to the therapy; The present invention relates to a method for determining whether to treat a patient suffering from cancer with immunochemotherapy or immunotherapy, comprising:

[0023] In a fourteenth aspect, the present invention relates to a kit for selecting a patient suffering from cancer to benefit from immunochemotherapy or immunotherapy, comprising detecting in a blood sample of a patient suffering from cancer the miR-2115-3p, the miR-218-5 ... (miR-4676-3p), SEQ ID NO: 34 (miR-6503-5p), fragments thereof, and sequences having at least 80% sequence identity thereto, wherein the patient optionally has a PD-L1 Tumor Proportion Score (TPS) of ≧50%.

[0024] This summary of the invention does not necessarily describe all features of the invention. Other embodiments will become apparent by consideration of the following detailed description.

[0025] [Detailed Description of the Invention] definition Before the invention is described in detail below, it is to be understood that this invention is not limited to the particular methodology, protocols, and reagents described herein, as these may vary. Also, it is to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0026] Preferably, the terms used herein are defined as set forth in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", Leuenberger, HGW, Nagel, B. and Kolbl, H. eds. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland.

[0027] Several documents are cited throughout the text of this specification. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, GenBank Accession Number sequence submissions, etc.), whether supra or infra, is incorporated herein by reference in its entirety. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such disclosure by prior invention. In the event of a conflict between a definition or teaching of such incorporated reference and a definition or teaching set forth herein, the text of this specification shall control.

[0028] In accordance with the present invention, the term "comprise" or variations such as "comprises" or "comprising" means the inclusion of a specified integer or group of integers, but does not mean the exclusion of any other integer or group of integers. In accordance with the present invention, the term "substantially comprising" means the inclusion of a specified integer or group of integers, but excludes modifications or other integers that substantially affect or change the specified integer. In accordance with the present invention, the term "consisting of" or variations such as "consists of" means the inclusion of a specified integer or group of integers, but excludes any other integer or group of integers.

[0029] As used in the context of describing the present invention (particularly in the context of the claims), the terms "a" and "an" and "the" and similar references should be interpreted to cover both the singular and the plural, unless otherwise indicated in the specification or clearly contradicted by context.

[0030] As used herein, the term "about" refers to a certain variation from the quantitative value that it precedes. In particular, the term "about" allows for a ±5% variation from the quantitative value it precedes, unless otherwise indicated or inferred. The use of the term "about" also includes the specific quantitative value itself, unless otherwise indicated. For example, the expression "about 80°C" allows for a ±4°C variation, and thus refers to a range of 76°C to 84°C.

[0031] As used herein, the term "biomarker" refers to a biological molecule found in blood, other bodily fluids, or tissues that is an indicator of a normal or abnormal process, or a condition or disease. Biomarkers can be used to predict how well the body will respond to treatment of a disease or condition, or to associate a particular disease or condition - or disease outcome - with a particular value of the biomarker found, for example, in a blood sample. Biomarkers are also called molecular markers and signature molecules. When a biomarker is used to predict the likely course and outcome of a disease, it may be called a prognostic biomarker. The biomarker described herein is a miRNA. The miRNA is a predictive and prognostic biomarker.

[0032] The term "miRNA" (which may also be referred to as "microRNA"), as used herein, refers to a single-stranded RNA molecule of at least 10 nucleotides and no more than 45 nucleotides covalently linked together. Preferably, the polynucleotides used in the present invention are molecules that are 10-45 nucleotides or 15-35 nucleotides long, more preferably 16-28 nucleotides or 18-23 nucleotides long, i.e., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45 nucleotides long, and optionally do not include labeled and / or extended sequences (e.g., biotin stretches). The miRNAs regulate gene expression and are encoded by genes whose DNA they are transcribed from, but they are not translated into proteins (i.e., miRNAs are non-coding RNAs). The genes that encode miRNAs are longer than the mature processed miRNA molecules. The miRNAs are initially transcribed as longer precursor molecules (>1000 nucleotides long) called primary miRNA transcripts (pri-miRNAs). Pri-miRNAs have hairpin structures and are processed by the Drosha enzyme (as part of the microprocessor complex). After Drosha processing, pri-miRNAs are only 60-100 nucleotides long and are called precursor miRNAs (pre-miRNAs). At this point, the pre-miRNAs are transported to the cytoplasm where they encounter the Dicer enzyme. Dicer cleaves the miRNA in two, generating a double-stranded miRNA strand. Traditionally, only one of these miRNA arms was thought to be important for gene regulation: the arm that is destined to be loaded into the RNA-induced silencing complex (RISC) and occurs in high concentrations within the cell. This is often called the "guide" strand, and is referred to as the miR. The other arm is called the "minor miRNA" or "passenger miRNA," and is often referred to as the miR. ★Passenger miRNAs were thought to be completely degraded, but detailed sequencing studies revealed that some minor miRNAs remain and indeed play a functional role in gene regulation. These developments led to a change in nomenclature. miR / miR ★ Instead of the nomenclature of miR-5p / miR-3p, the nomenclature of miR-5p / miR-3p has been adopted. In the new system, the 5' arm of a miRNA is always called miR-5p and the 3' arm is called miR-3p. The current nomenclature is as follows: the prefix "miR" followed by a dash and a number, the latter often indicating the order of naming. For example, hsa-miR-16 was likely named and discovered before hsa-miR-342. Capitalized "miR-" refers to the mature form of the miRNA (e.g., hsa-miR-16-5p and hsa-miR-16-3p), while uncapitalized "mir-" refers to the pre-miRNA and pri-miRNA (e.g., hs a-miR-16), and "MIR" refers to the genes that encode them. However, this is a recent change, so literature often refers to the original miR / miR* names. After processing, the double-stranded miRNA strand is loaded onto Argonaute (AGO) proteins to form the precursor of RISC. This complex unwinds the duplex, discarding the passenger RNA strand and leaving the mature RISC with the mature single-stranded miRNA. The miRNA remains part of the RISC as it represses the expression of target genes. This is the canonical pathway for miRNA biogenesis, but various other pathways have been discovered. These include the Drosha-independent pathway (such as the mirtron pathway, the snoRNA-derived pathway, and the shRNA-derived pathway) and the Dicer-independent pathway (such as the pathway that relies on AGO for cleavage and the pathway that relies on tRNaseZ).

[0033] The term "miRBase" as used herein refers to a well-established repository of validated miRNAs. miRBase (www.mirBase.org) is a searchable database of published miRNA sequences and annotations. Each entry in the mirBase sequence database represents a predicted hairpin portion of a miRNA transcript (referred to in the database as miR), along with location and sequence information of the mature miRNA sequence (referred to as miR). Both hairpin and mature sequences are available for searching and viewing, and entries can also be searched by name, keywords, references, and annotations. All sequence and annotation data can also be downloaded.

[0034] The miRNAs described herein have a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, even more preferably at least 95%, and even more preferably at least 99%, e.g., at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto.

[0035] Residues in two or more polynucleotides are said to "correspond" to each other if the residues occupy similar positions in the polynucleotide structure. It is well known in the art that similar positions in two or more polynucleotides can be determined by aligning the polynucleotide sequences based on nucleic acid sequence or structural similarity. Such alignment tools are well known to those skilled in the art and can be obtained, for example, on the World Wide Web, for example, ClustalW or Align using standard settings, preferably Align EMBOSS::needle, Matrix:Blosum62, Gap Open 10.0, Gap Extend 0.5.

[0036] The term "disease" as used herein refers to an abnormal condition that affects an individual's body. A disease is often interpreted as a medical condition associated with certain symptoms and signs. In humans, the term "disease" is often used more broadly to refer to any condition that causes pain, dysfunction, suffering, social problems, or death to the affected individual, or similar problems to those in contact with the individual. In this broad sense, it may include injuries, disorders, disorders, syndromes, infections, deviant behaviors, and atypical changes in structure and function, although in other contexts and for other purposes, these may be considered as identifiable categories. Illnesses usually affect individuals not only physically but also emotionally, as suffering from and living with many illnesses can change one's outlook on life and personality.

[0037] As used herein, the term "cancer" refers to or describes a physiological condition in an individual that is typically characterized by unregulated cell proliferation. Examples of cancer include, but are not limited to, lung cancer, preferably non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLS), breast cancer, cervical cancer, gastric cancer, These include bladder cancer, skin cancer, nasopharyngeal cancer, neuroendocrine cancer, colon cancer, urothelial cancer, liver cancer, ovarian cancer, esophageal cancer, pancreatic cancer, kidney cancer, stomach cancer, esophageal cancer, renal cancer, head and neck cancer, brain cancer, lymphatic cancer, blood cancer, squamous cell carcinoma, laryngeal cancer, retinal cancer, prostate cancer, uterine cancer, testicular cancer, bone cancer, lymphoma, and leukemia. The term "cancer" as used herein also includes cancer metastasis.

[0038] The term "lung cancer" as used herein refers to a disease consisting of uncontrolled cell proliferation in the tissues of the lung. This proliferation can lead to metastasis, which is the invasion of adjacent tissues and beyond the lung. The majority of primary lung cancers are lung cancers originating from epithelial cells. Lung cancer is the most common cause of cancer-related death in both men and women. The most common symptoms are shortness of breath, cough (including hemoptysis), and weight loss. The lung cancer may be late-stage lung cancer, particularly stage IV lung cancer. The main types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Preferably, the lung cancer is NSCLC, particularly stage IV.

[0039] The term "tumor" as used herein refers to the growth and proliferation of lesions and neoplastic cells, and all pre-cancerous and cancerous cells and tissues resulting in abnormal tissue growth, whether malignant or benign.

[0040] The term "therapeutic treatment / therapy" as used herein relates to any treatment / therapy that improves the health status and / or extends (increases) the lifespan of a patient. The treatment / therapy may eliminate the disease in a patient, may halt, inhibit or delay the onset of the disease in a patient, may reduce the frequency or severity of symptoms in a patient, and / or may reduce recurrence in a patient who currently or previously had the disease.

[0041] As used herein, the term "cancer therapy" refers to any protocol, method, and / or agent that can be used in the prevention, management, treatment, and / or amelioration of cancer. In particular, as used herein, the term "cancer therapy" refers to achieving one or more of the following: (i) Tumor growth inhibition and / or tumor cell death (ii) Reduction in tumor markers (iii) Inhibition of tumor lesions and metastasis (iv) a reduction in tumor burden as evidenced by imaging studies (e.g., computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), etc.); and (v) Reduction in tumor burden as evidenced by clinical assessment or self-report by the patient. Specifically, cancer treatments include, but are not limited to, drug therapy, supportive therapy, and / or other therapies useful in the prevention, management, treatment, and / or amelioration of cancer known to those skilled in the art, such as medical practitioners. More specifically, cancer treatments include, but are not limited to, immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, anti-hormonal therapy, immunosuppressive therapy, antibody therapy, and / or surgical therapy. Even more specifically, cancer treatments are immunotherapies.

[0042] The term "chemotherapy" as used herein refers to a type of cancer treatment that uses one or more anti-cancer drugs, also known as chemotherapy drugs, as part of a standardized chemotherapy regimen. Chemotherapy can be administered with the intent of cure (preferably involving a combination of drugs) or with the intent of prolonging life or reducing symptoms (palliative chemotherapy). Preferably, the chemotherapy is a platinum doublet chemotherapy.

[0043] As used herein, the term "chemotherapeutic agent" refers to any agent that directly or indirectly inhibits the uncontrolled growth and proliferation of cancer cells. Chemotherapeutic agents include, but are not limited to, alkylating agents, antimetabolites, folinic acid, antifolates, mitotic inhibitors, antagonizing agents, and the like. These include lacyclines, topoisomerase inhibitors, antibodies, signal transduction inhibitors, inhibitors of angiogenesis, and / or inhibitors of histone deacetylase.Preferably, the chemotherapeutic agent is a platinum doublet.

[0044] The term "radiotherapy" as used herein refers to a type of cancer treatment that uses ionizing radiation to control or kill cancerous / malignant cells. Ionizing radiation is usually delivered by a linear accelerator. Radiation therapy can be curative for some types of cancers if they are localized to one area of ​​the body. It may also be used as part of adjuvant therapy to prevent tumor recurrence after surgery to remove the primary malignant tumor. Radiation therapy is synergistic with chemotherapy and can be used before, during, or after chemotherapy in sensitive cancers.

[0045] The term "immunotherapy" refers to any treatment in which one or more components of the human or animal immune system are intentionally modulated to achieve some therapeutic benefit, directly or indirectly, including systemic and / or local effects, as well as preventive and / or curative effects. Immunotherapy can include administering one or more immunotherapeutic drugs or agents, alone or in any combination, to a human or animal subject, whether systemic, local, or both, by any route (e.g., oral, intravenous, cutaneous, injection, inhalation, etc.). Immunotherapy can include inducing, increasing, decreasing, stopping, preventing, blocking, or otherwise modulating the production of cytokines, and / or activating or inactivating cytokines or immune cells, and / or modulating the levels of immune cells, and / or delivering one or more therapeutic or diagnostic substances to a specific location or type of cell or tissue in the body, and / or destroying a specific cell or tissue. Immunotherapy can be used to achieve a local effect, a systemic effect, or a combination of both, and can also be used to reduce or eliminate side effects that may be caused by other anti-cancer therapies.

[0046] Immunotherapies designed to induce or amplify an immune response are classified as activating immunotherapies, while immunotherapies that decrease or suppress an immune response are classified as suppressing immunotherapies.

[0047] Antitumor immunotherapy has broad potential to induce durable and robust responses across a range of malignancies and can therefore be used to treat many different types of advanced cancers.

[0048] Immunotherapy involves the administration of an immunotherapeutic agent.

[0049] The term "immunotherapeutic agent" as used herein refers to any drug, compound, or biological agent that indirectly or directly restores, enhances, stimulates, or increases the body's immune response to cancer cells and / or reduces the side effects of other anti-cancer therapies. Examples of common immunotherapeutic agents known in the art include, but are not limited to, checkpoint inhibitors, cytokines, cancer vaccines, antibodies such as monoclonal antibodies, and / or non-cytokine adjuvants. Alternatively, or in addition, immunotherapeutic treatment involves the administration of immune cells (e.g., T cells, NK cells, cells, dendritic cells, B cells, etc.) to the patient. In particular, the immune cells are antigen-presenting cells and / or chimeric antigen receptor T cells.

[0050] Immunotherapeutic agents may be non-specific, i.e., they may generally boost the immune system so that the body is more effective at fighting the growth and / or spread of cancer cells, or they may be specific, i.e., they may target the cancer cells themselves. Immunotherapy regimens may combine the use of non-specific and specific immunotherapeutic agents.

[0051] Nonspecific immunotherapeutic agents are substances that stimulate or indirectly improve the immune system. Nonspecific immunotherapeutic agents are used both alone as a primary therapy for the treatment of cancer, as well as in addition to primary therapy. In some cases, non-specific immunotherapeutic agents act as adjuvants to enhance the efficacy of other therapies (e.g., cancer vaccines). Non-specific immunotherapeutic agents may also function in this latter context to reduce the side effects of other therapies, such as bone marrow suppression induced by certain chemotherapeutic agents. Non-specific immunotherapeutic agents can act on important immune system cells and trigger secondary responses, such as increased production of cytokines and immunoglobulins. Alternatively, these agents themselves can contain cytokines. Non-specific immunotherapeutic agents are generally classified as cytokine or non-cytokine adjuvants. Many cytokines have been applied in cancer treatment as general non-specific immunotherapies designed to boost the immune system or as adjuvants provided with other treatments. Suitable cytokines include, but are not limited to, interferons, interleukins, and / or colony stimulating factors. Interferons (IFNs) include, for example, IFN-α (IFN-α), IFN-β (IFN-β), and / or IFN-γ (IFN-γ). Interleukins include, for example, IL-2, IL-4, IL-11, and / or IL-12. Colony-stimulating factors (CSFs) include, for example, granulocyte colony-stimulating factor (G-CSF or filgrastim), granulocyte-macrophage colony-stimulating factor (GM-CSF or sargramostim), and / or erythropoietin (epoetin alpha, darbopoietin).

[0052] Furthermore, immunotherapeutic agents can be active, i.e., stimulate the body's own immune response, including humoral and cellular immune responses, or they can be passive, i.e., involve immune system components such as antibodies, effector immune cells, antigen-presenting cells, etc., generated outside the body. In particular, passive immunotherapy involves the use of one or more monoclonal antibodies that are specific for a particular antigen found on the surface of cancer cells or immune cells, or that are specific for a particular cell growth factor. Monoclonal antibodies can be used in cancer treatment in many ways, for example, to enhance a subject's immune response to a particular type of cancer, to disrupt the growth of cancer cells by targeting a particular cell growth factor, such as one involved in angiogenesis, or by enhancing the delivery of other anti-cancer agents to cancer cells when linked or bound to agents such as chemotherapeutic agents, radioactive particles, or toxins.

[0053] Tumors are known to evade immune-mediated recognition through multiple mechanisms of immune escape. Upon chronic exposure to tumor antigens, T cells become dysfunctional / exhausted and upregulate various checkpoint inhibitory receptors (IRs) that limit T cell survival and function. Thus, immunotherapy specifically encompasses approaches to treat cancer by stimulating T cell function and preventing T cell death. This approach is based on the surprising finding that stimulation of T cell function with compounds, e.g., antibodies, that block or activate regulatory receptors may be sufficient to cause tumor regression. Checkpoint blockade is, for example, a method in which T cell function is stimulated with compounds that block their inhibitory receptors, while T cell costimulation is a method that aims to activate T cell function with compounds that target their stimulatory receptors. Immunotherapeutics as described herein specifically encompass the administration of checkpoint inhibitors.

[0054] In one embodiment of the present invention, the immunotherapeutic agent is a PD-1 / PD-L1 inhibitor. In one preferred embodiment of the present invention, the PD-1 / PD-L1 inhibitor is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, durvalumab, and atezolizumab. In this regard, it should be noted that pembrolizumab and nivolumab specifically target the PD-1 protein, whereas atezolizumab, durvalumab, and avelumab specifically target the PD-L1 ligand. PD-1 means programmed cell death protein 1, and PD-L1 means programmed cell death ligand 1. PD-1 is the receptor for the ligand PD-L1.

[0055] The term "immune checkpoint inhibitor" as used herein refers to any compound that reduces, inhibits, interferes with, or modulates one or more immune checkpoint proteins, either in whole or in part. Inhibition includes reduced function and complete blockage. Many immune checkpoint inhibitors are known, and alternative immune checkpoint inhibitors may be developed in the (near) future, as well as these known immune checkpoint protein inhibitors. Immune checkpoint inhibitors include, but are not limited to, peptides, antibodies, nucleic acid molecules, and / or small molecules. Preferably, the immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), programmed cell death ligand 2 (PD-L2), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), LAG3 (lymphocyte activation gene-3), TIGIT (T cell immunoreceptor with immunoglobulin and ITIM domains), CD73 (ecto-5'-nucleotidase (NT5E)), and endogenous checkpoint blockade. More preferably, the inhibitor targeting PD-L1 is selected from the group consisting of atezolizumab, durvalumab, and avelumab, and the inhibitor targeting PD-1 is selected from the group consisting of pembrolizumab and nivolumab.

[0056] The term "prediction" as used herein refers to a prognosis of whether a patient will respond to a cancer treatment or achieve a clinical outcome in response to a cancer treatment. In some embodiments, a positive response to the cancer treatment is predicted. In some alternative embodiments, a negative response to the cancer treatment is predicted. The prediction of a patient's response to a cancer treatment is usually performed before treating the patient with a cancer treatment. If the predicted result is positive, the patient will receive the cancer treatment. If the predicted result is negative, the patient will not receive the cancer treatment or will receive a different cancer treatment. For example, if a patient suffering from cancer is predicted not to respond to immunotherapy, the patient may be treated with another therapy other than immunotherapy, such as radiation therapy and / or chemotherapy. However, the prediction of the response to a cancer treatment can also be performed after the initiation of the cancer treatment. If the predicted result is positive, the cancer treatment is continued. If the predicted result is negative, the cancer treatment is modified or discontinued.

[0057] In particular, the method described herein for predicting the response of a patient suffering from cancer to a cancer treatment is suitable for distinguishing patients who respond to a cancer treatment from those who do not respond to the cancer treatment. Typically, the characterization of a patient as a responder or non-responder can be performed by referring to a standard or training set. The standard can be a profile of subjects known to be responders or non-responders, or it can be a numerical value / reference level. Such a predefined standard can be provided in any suitable form, such as a printed list or diagram, a computer software program, a mathematical algorithm, or other medium. If the patient is predicted to be a responder, the physician can make a decision to administer a cancer treatment, such as an immunotherapy, to the patient. If the patient is predicted to be a non-responder, the physician can make a decision not to administer the cancer treatment, but to administer another cancer treatment instead. In this case, further adverse side effects can be avoided.

[0058] The present inventors have identified novel miRNA biomarkers that allow prediction of the response of patients suffering from cancer to cancer treatment. The miRNAs have a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80% sequence identity thereto. The cancer treatment is preferably immunotherapy.

[0059] As used herein, the term "response" refers to a change in a patient's condition that occurs as a result of or correlates with cancer treatment. In some embodiments, the response is or includes a beneficial response. In some embodiments, a beneficial response includes stabilization of a condition (e.g., a cure), or a treatment that is more effective than ... The response may include, for example, prevention or delay of progression expected or typically observed in the absence of treatment, amelioration of one or more symptoms of the condition (e.g., reduction in frequency and / or intensity), and / or improvement in the likelihood of a cure for the condition, etc. In particular, the response is the response of a patient suffering from cancer to immunotherapy.

[0060] Specifically, a cancer patient or (control) subject suffering from cancer who has been treated with a cancer therapy is considered to "respond," "have a response," have a "positive response," or "respond" to the cancer therapy if the individual shows evidence of an anti-cancer effect according to a set of objective criteria accepted in the art, or reasonable modifications thereof, including a clinically significant benefit such as prevention or reduction in severity of symptoms, or delay in progression of cancer. It is understood that the above terms may also be used in relation to cancer.

[0061] A variety of different objective criteria for evaluating the effect of anticancer treatment on cancer are known in the art. The World Health Organization (WHO) criteria (Miller, AB, et al., Cancer 1981; 47(1): 207-14) and its revised version, the Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse P, et al., J Natl Cancer Inst 2000; 92: 205-16) and its revised version (Eisenhauer EA, New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-47) are a set of objective criteria based on the image determination of the size and number of tumor lesions, and the detection of new lesions, for example, from computed tomography (CT), magnetic resonance imaging (MRI), or conventional X-ray. The dimensions of selected lesions (called target lesions) are used to calculate the change in tumor burden between images from different time points. The calculated response is then classified as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). CR is the complete disappearance (-100%) of the tumor, PD is an increase of about 20-25% or more (depending on the specified criteria) and / or the appearance of new lesions. PR is a significant (at least about 30%) reduction in the size of the tumor lesion (without the appearance of new lesions) but short of a complete response, and SD is intermediate between PR and PD.

[0062] However, in some cases, an anatomical image alone may not be sufficient. For example, meaningful tumor responses to immunotherapy, such as with immune checkpoint inhibitors, may occur after a delay, in some cases according to the WHO or RECIST criteria mentioned above. The immune-related response criteria (irRC) were defined to capture additional favorable response patterns observed with immunotherapy (Wolchok, JD, et al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Care Res. 15, 7412-7420.). The developers of irRC based their criteria on the WHO criteria, but modified them. In irRC, tumor burden is measured by combining "index" lesions and new lesions. Typically, tumor burden is simply measured with a limited number of "index lesions" (i.e., the largest identifiable lesions) at baseline, and new lesions identified at subsequent time points are counted as "disease progression." In contrast, in irRC, new lesions are simply a change in tumor burden. The irRC maintained the bidirectional measurement of disease originally defined by the WHO criteria. In the irRC, an immune-related complete response (irCR) is the disappearance of all disease, measured or not, and no new disease is identified, an immune-related partial response (irPR) is a 50% decrease in tumor burden from irRC-defined baseline, and an immune-related progressive disease (irPD) is a 25% increase in tumor burden from the lowest level recorded. All others are considered immune-related stable disease (irSD). The idea here is that even if the tumor burden is increasing, the immune system will likely "kick in" several months after the first dose, eventually resulting in a decline in tumor burden in many patients. The 25% threshold allows for this apparent delay to be taken into account.

[0063] irRC is applicable to immune checkpoint inhibitors and other immunotherapeutic agents. One skilled in the art will appreciate that various factors may be considered as indicators of tumor viable tissue, such as the degree of tumor arterial enhancement and / or change in tumor density, where decreased arterial enhancement and decreased tumor density are indicators of decreased viable tumor tissue (e.g., due to tumor necrosis), and additional response criteria are known in the art.

[0064] In contrast, a cancer patient or (control) subject suffering from cancer who has been treated with a cancer therapy is considered to be "unresponsive," "unresponsive," "has a negative response," or is "non-responsive" to the cancer therapy if the therapy does not provide a clinically significant benefit, such as prevention or reduction in the severity of symptoms, or does not increase the rate of cancer progression.

[0065] As used herein, the term "prognosis" means the chance of recovery from a disease or a prediction of the likely development or outcome of a disease, including, but not limited to, prediction of patient survival, particularly overall survival, the chance of cancer recurrence in a patient, and the chance of tumor metastasis.

[0066] The term "prognosis" as used herein refers to the prediction of the possibility / probability of death of a patient suffering from cancer. In particular, the term "provide prognosis for a patient suffering from cancer" as used herein means determining whether the patient has a good prognosis (low probability of death) or a bad prognosis (high probability of death) with respect to cancer. The patient is preferably a patient who is to be administered, has been administered, or has been administered a cancer treatment. Prognosis can be defined as predicted overall survival (OS) and / or survival at 2 or 5 years of follow-up. Possibility / probability of survival can be expressed as a value between 0% and 100%, where 100% is a high possibility / probability of survival for the indicated period (good prognosis) and 0% is a low probability / probability of survival for the indicated period (bad prognosis). The time period indicated may be (at least / at most) 3 months, 6 months, 9 months, 12 months (1 year), 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years.

[0067] Specifically, a good life prognosis is associated with a high possibility / probability of surviving for a certain period of time. More specifically, a patient with a good prognosis has a possibility / probability of more than 50%, preferably more than 60%, more preferably more than 70%, even more preferably more than 80%, even more preferably more than 90%, or most preferably more than 95% to survive for a certain period of time. The certain period of time is preferably (at least) 3 months, 6 months, 9 months, 12 months (1 year), 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years.

[0068] Specifically, poor life prognosis is associated with a low possibility / probability of surviving for a certain period of time.More specifically, a patient with poor prognosis has a possibility / probability of 50% or less, preferably 40% or less, more preferably 30% or less, even more preferably 20% or less, even more preferably 10% or less, and most preferably 5% or less to survive for a certain period of time.Preferably, the certain period of time is (at most) 3 months, 6 months, 9 months, 12 months (1 year), 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years.

[0069] Alternatively, a patient suffering from cancer is predicted to have a short or long survival time. The term "short survival time", e.g. (at most) 3 months, 6 months, 9 months, or 12 months (1 year), indicates that the patient has a survival time that is shorter than the median (or mean) observed in the general population of (control) subjects suffering from said cancer. Patients have a short survival time. If the patient has a long survival time, it means that the patient has a "poor prognosis". Conversely, the term "long survival time", for example (at least) 2 years, at least 5 years, at least 8 years, or at least 10 years, indicates that the patient has a higher survival time than the median (or average) observed in the general population of (control) subjects suffering from said cancer. If the patient has a long survival time, it means that the patient has a "good prognosis". For example, a patient predicted to have a short survival time is no longer alive at 2 or 5 years of follow-up, while a patient predicted to have a long survival time is still alive at 2 or 5 years of follow-up. Those skilled in the art will recognize that "overall survival (OS)" time is generally based on and expressed as the percentage of people who survive a particular type of cancer during the indicated period. In cancer statistics, 2-year or 5-year overall survival rates are often used. In a specific embodiment, a patient with a good prognosis survives for a period of 2 or 5 years. A patient with a poor prognosis does not survive for a period of 2 or 5 years.

[0070] The method of providing a life prognosis to a patient suffering from cancer is, for example, a useful tool for predicting whether an individual is likely to survive (overall or long-term) after treatment. The method can also be used clinically to make treatment decisions by selecting the most appropriate treatment for any particular patient suffering from cancer. The treatment can be selected from the group consisting of immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, anti-hormonal therapy, immunosuppressive therapy, antibody therapy, and surgical therapy.

[0071] Kaplan-Meier analysis is a statistical method recommended for survival analysis. It is applied by analyzing the distribution of survival times of patients after enrollment in the study. The analysis expresses these as the percentage of patients surviving to a given time point after enrollment. On a graph, when the percentage of surviving patients is plotted against time, there is a characteristic decline (often exponential), the steepness of the curve indicating the effectiveness of the treatment under investigation. The shallower the survival curve, the more effective the treatment. Kaplan-Meier analysis can be used to test the statistical significance of the difference between survival curves associated with two different treatments.

[0072] Through such analysis, the inventors have identified new miRNA biomarkers that can provide prognosis for patients suffering from cancer. These miRNAs have nucleotide sequences selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80% sequence identity thereto. The inventors have found that the miRNAs are discriminators for survival of cancer patients undergoing cancer treatment. These are prognostic indicators that allow stratifying / classifying high-risk and low-risk patients.

[0073] The term "PD-L1 Tumor Proportion Score (TPS)" as used herein refers to the percentage of PD-L1 positive tumor cells among all viable tumor cells. Thus, to determine the PD-L1 Tumor Proportion Score (TPS), all tumor cells that stain membrane-bound positive for PD-L1 are counted and divided by the total number of tumor cells (the percentage value of positive tumor cells). The TPS of PD-L1 may be a decision criterion in the selection of a treatment regimen. In particular, the treatment regimen of a patient suffering from a cancer with a PD-L1 TPS of ≥ 50% may be different from that of a patient suffering from a cancer with a PD-L1 TPS of < 1% and / or from that of a patient suffering from a cancer with a PD-L1 TPS of 1-49%.

[0074] For example, in later stage lung cancer, such as stage IV NSCLC, patients with a PD-L1 TPS of <1% are usually treated with chemotherapy, and patients with a PD-L1 TPS of 1-49% are usually treated with immunochemotherapy.

[0075] Currently, both immunotherapy and immunochemotherapy are recommended as treatment options for patients with advanced lung cancer, such as stage IV NSCLC with PD-L1 TPS ≥ 50%. A subset of the approximately 60% of patients who do not respond to immunotherapy may benefit from immunochemotherapy, as chemotherapy may sensitize the tumor with immunotherapy. However, this additional treatment burden comes at the cost of increased frequency and severity of toxicity, with approximately 70% of patients experiencing grade 3-4 adverse events. The choice between immunotherapy and immunochemotherapy remains largely based on clinical judgment. Factors considered include performance status, number of metastatic sites, and aggressiveness of disease. However, the optimal treatment remains largely unclear.

[0076] The inventors have solved this problem and defined a (miRisk) cut-off score that allows identifying patients who will benefit from immunochemotherapy treatment rather than immunotherapy. In this way, patients only need to receive immunotherapy in combination with the high physical stress associated with chemotherapy if they really need it. This (miRisk) cut-off score therefore allows for therapeutic decisions as a complementary diagnostic.

[0077] As used herein, the term "patient" refers to any individual suffering from cancer who desires to know whether she or he will respond to a cancer treatment. It may be possible to predict whether a patient suffering from cancer will respond to a cancer treatment or will not respond to a cancer treatment. If a patient is identified as a patient who will respond to a cancer treatment, the patient is assigned to the cancer treatment. If a patient is identified as a patient who will not respond to a cancer treatment, the patient is not assigned to said cancer treatment, but may be assigned to an alternative cancer treatment.

[0078] As used herein, the term "patient" also refers to any individual suffering from cancer for whom it is desired to know the prognosis. Patients suffering from cancer can be determined to have a good or bad prognosis.

[0079] The term "patient" as used herein also refers to any individual suffering from cancer, and it is desired to know how cancer develops in the patient.The patient can be monitored, for example, in the form of longitudinal monitoring.Therefore, the progress of cancer (particularly after or during treatment) can be observed in the patient.

[0080] The term "patient" as used herein also refers to any individual suffering from cancer for whom it is desirable to know whether the patient will (are likely to) benefit from immunotherapy or immunochemotherapy (i.e., patient selection / stratification).

[0081] The patient can be any mammal, including both humans and other mammals, such as rabbits, mice, rats, or monkeys, with human patients being particularly preferred.

[0082] The term "(control) subject" as used herein refers to an individual suffering from cancer who is a known responder or non-responder to a cancer treatment. The term "(control) subject" as used herein also refers to an individual suffering from cancer who has a known good or bad life prognosis. The (control) subject can be any mammal, including both humans and other mammals, such as rabbits, mice, rats, or monkeys. Human control subjects are particularly preferred.

[0083] The term "blood sample" as used herein includes whole blood or blood fractions. Preferably, the blood fraction is selected from the group consisting of blood cell fractions, plasma, and serum. In particular, the blood fraction is selected from the group consisting of blood fractions and plasma or serum. For example, the blood cell fraction includes red blood cells, white blood cells, and / or platelets. More preferably, the blood cell fraction is a white blood cell fraction. In particular, the white blood cells include myeloid cells and / or lymphocytes. More particularly, the myeloid cells include granulocytes, monocytes, macrophages, and dendritic cells (DCs). or a combination thereof. Preferably, the blood sample has a volume of 0.01 to 20 mL, more preferably 0.1 to 10 mL, even more preferably 0.5 to 8 mL, and most preferably 1 to 5 mL.

[0084] The blood sample can be provided by drawing blood from the patient or (control) subject, but also by using a previously isolated sample, for example, the blood sample can be taken from the patient or (control) subject by conventional blood collection techniques.

[0085] The blood sample can further be obtained from a patient or (control) subject before the start of therapeutic treatment, during therapeutic treatment, and / or after therapeutic treatment. When a blood sample is obtained from at least one (control) subject, for example at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 400, 500, or 1,000 (control) subjects, it is called a "reference blood sample". Preferably, the reference blood sample is from the same source as the blood sample of the patient being tested, for example both are whole blood samples or blood cell fractions. Furthermore, it is preferred that both are from the same species, for example human. It is also preferred (alternatively or additionally) that the measurements of the reference blood sample of the (control) subject and the blood sample of the patient being tested are identical, for example both have the same volume. It is particularly preferred that the reference blood sample and the blood sample are from (control) subjects / patients of the same sex and similar age.

[0086] Whole blood samples can be collected by blood collection tubes, for example, PAXgene blood RNA tubes, Tempus blood RNA tubes, EDTA tubes, Na-citrate tubes, heparin tubes, or ACD tubes (acid citrate-dextrose).

[0087] Whole blood samples can also be collected by blood spot technology, for example using the Mitra microsampling device. This technology requires smaller sample volumes, typically 45-60 μL or less for humans. For example, whole blood can be extracted from a patient by pricking a finger with a needle or lancet. Thus, the whole blood sample can have the form of a blood drop. The blood drop is then placed on an absorbent probe, for example a hydrophilic polymeric material such as cellulose that can absorb whole blood. Once sampling is complete, the blood spot is dried in air before being transported or sent to a laboratory for processing. Since blood is dry, it is not considered hazardous. Therefore, no special precautions need to be taken in handling or sending it. Once it reaches the analysis site, the desired components, for example miRNA, are extracted from the dried blood spot into the supernatant and then further analyzed. This technology is suitable for monitoring patients with cancer at home (based on home care / home sampling) or for screening purposes.

[0088] The term "myeloid cells" as used herein refers to a subgroup of white blood cells. This subgroup includes granulocytes, monocytes, macrophages, and dendritic cells (DCs). In other words, granulocytes, monocytes, macrophages, and dendritic cells (DCs) are collectively referred to as myeloid cells. In one embodiment, the myeloid cells are selected from the group consisting of granulocytes, monocytes, macrophages, and dendritic cells (DCs), or a combination thereof. Myeloid cells circulate through the blood and lymphatic system and are rapidly recruited to sites of tissue damage, including tumor-associated tissue damage, and to sites of infection via various chemokine receptors. Thus, myeloid cells are an important arm of the immune system and are largely involved in the natural defense against a range of pathogens. Myeloid cells also play a key role in linking innate and adaptive immunity, mainly through antigen presentation and recruitment of adaptive immune cells. As described above, the inventors have developed a method for predicting survival and response by using myeloid cells. In this study, novel miRNA biomarkers for bone marrow cell differentiation have been identified, some of which are specifically / exclusively present in myeloid cells. These miRNAs have nucleotide sequences selected from the group consisting of SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:34, SEQ ID NO:38, SEQ ID NO:41 to SEQ ID NO:44, fragments thereof, and sequences having at least 80% sequence identity thereto. The above miRNAs are herein designated as myeloid miRNAs.

[0089] In the methods described herein, the level of miRNA is determined in a blood sample of a patient. The term "level" as used herein refers to the amount (e.g., measured in grams, moles, or ion counts) or concentration (e.g., absolute or relative concentration, e.g., reads per million (RPM) or NGS counts) of miRNA. The term "level" as used herein also includes scaled, normalized, or scaled and normalized amounts or values ​​(e.g., RPM). In particular, the level of miRNA is determined by sequencing, preferably next-generation sequencing (e.g., ABI SOLID, Illumina Genome Analyzer, Roche 454 GS FL, BGISEQ), nucleic acid hybridization (e.g., microarray or bead), nucleic acid amplification (e.g., PCR, RT-PCR, qRT-PCR, or high-throughput RT-PCR), polymerase extension, mass spectrometry, flow cytometry (e.g., Luminex), or any combination thereof. In particular, the level of miRNA is the expression level of said miRNA.

[0090] Those skilled in the art will understand that in many embodiments described herein, the determined miRNA level is compared to a suitable miRNA "reference level". Specifically, the miRNA level is compared to the reference level of the miRNA. More specifically, the miRNA reference level is determined in a blood sample of a (control) subject. Even more specifically, the reference level is empirically determined by measuring multiple reference blood samples from subjects suffering from cancers known to be responders or non-responders to cancer treatment, or by measuring multiple reference blood samples from subjects suffering from cancers with known good or bad life prognosis. Typically, as will be understood by those skilled in the art, the reference level is determined under conditions comparable to those utilized to determine or analyze miRNA levels in patient blood samples.

[0091] The reference level can also be a cut-off or threshold level of miRNA. Typically, the cut-off or threshold level can be experimentally, empirically, or theoretically determined. The cut-off or threshold level can also be arbitrarily selected based on existing experimental and / or clinical conditions, as recognized by those skilled in the art. The cut-off or threshold must be determined to obtain optimal sensitivity and specificity according to the function of the test and the benefit / risk balance (false positive and false negative clinical outcomes). Typically, the optimal sensitivity and specificity (and therefore the threshold level) can be determined using a receiver operating characteristic (ROC) curve based on experimental data. For example, after determining the miRNA level in the reference group, algorithmic analysis can be used for statistical processing of the measured miRNA level in the sample to be tested, and thus a classification standard with significance for sample classification can be obtained. The formal name of the ROC curve is the receiver operator characteristic curve, and it is also known as the receiver operation characteristic curve. It is mainly used in clinical biomarker testing. The ROC curve is a comprehensive index that reflects the continuous variables of true positive rate (sensitivity) and false positive rate (1-specificity). The relationship between sensitivity and specificity was revealed by image synthesis techniques. A series of different cutoff or threshold levels were used. is set as a continuous variable and a series of sensitivity and specificity values ​​are calculated. A curve is then drawn using sensitivity as the vertical coordinate and specificity as the horizontal coordinate. The higher the area under the curve (AUC), the higher the accuracy of prediction / prognosis / diagnosis. The point on the ROC curve closest to the far top left of the coordinate plot is the critical point with both high sensitivity and high specificity values. The AUC value of the ROC curve is between 1.0 and 0.5. If AUC>0.5, the prediction / prognosis / diagnosis results are getting better and better as the AUC approaches 1. If the AUC is between 0.5 and 0.7, the accuracy is low. If the AUC is between 0.7 and 0.8, the accuracy is moderate. If the AUC is 0.8 or more, the accuracy is high. If the AUC is above 0.9, the accuracy is very high.

[0092] The term "classifier" as used herein refers to a predictive / prognostic model that allows distinguishing between samples or characterizing a given sample by classifying the sample into a predefined class based on certain characteristics of the sample. For example, the classification used herein can predict with relatively high sensitivity and specificity if a blood sample of a patient with unknown response prediction belongs to one of two predefined classes, each class representing a predicted estimated response. The output can be given as a probability of belonging to any of the classes 0 to 1. The classification used herein can also predict with relatively high sensitivity and specificity if a blood sample of a patient with unknown life prognosis belongs to one of two predefined classes, each class representing a predicted estimated survival. The output can be given as a probability of belonging to any of the classes 0 to 1. In particular, the classifier allows distinguishing between responders to cancer treatment and non-responders to cancer treatment. The classifier can also allow distinguishing between patients with poor life prognosis from patients with good life prognosis. Furthermore, the classifier may also make it possible to distinguish whether a patient should be assigned to and / or treated with immunotherapy or immunochemotherapy.

[0093] The term "pharmaceutical effective amount" as used herein refers to an amount that achieves the desired response or the desired effect, either alone or together with further doses. In the case of the treatment of a particular disease, the desired response preferably relates to the inhibition of the course of the disease. This includes slowing the progression of the disease, in particular interrupting or reversing the progression of the disease. The desired response in the treatment of a disease can also be the delay of the onset of the disease or the prevention of its onset. The effective amount described herein depends on the condition being treated, the severity of the disease, the individual parameters of the patient, including age, physiological state, size, and weight, the duration of the treatment, the type of concomitant treatment (if any), the specific route of administration, and similar factors. Thus, the dose may depend on various such parameters. If the patient does not respond adequately to the initial administration, a higher dose (or an effective higher dose obtained by another, more localized route of administration) may be used. The disease described herein is cancer, preferably lung cancer.

[0094] In the context of the present invention, the term "kit of parts" (short: kit) is understood to be any combination of at least some of the components identified herein, which are spatially coexistent and combined into a functional unit, and which may comprise further components.

[0095] EMBODIMENTS OF THE PRESENT DISCLOSURE The present invention will be further described below. In the following passages, various aspects of the present invention are defined in more detail. Each aspect thus defined can be combined with other aspects, unless expressly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous can be combined with any other feature indicated as being preferred or advantageous, unless expressly indicated to the contrary.

[0096] The present inventors have identified response and survival predictive miRNAs from whole blood for cancer therapy, especially immunotherapy. These novel miRNAs are useful for rapid and accurate clinical prediction in cancer diseases. Thus, said miRNAs can be used as companion or complementary diagnostics in cancer treatment, especially in immunotherapy. Furthermore, these new miRNAs make it possible to select patients suffering from cancer to benefit from immunochemotherapy or immunotherapy.

[0097] Thus, in a first aspect, the present invention provides a method for predicting a response to cancer treatment in a patient suffering from cancer comprising determining the level of at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 miRNA) in a blood sample of the patient suffering from cancer (I). In a further aspect, the present invention relates to an in vitro method for detecting miRNAs comprising the steps of: (a) detecting a miRNA in a mammalian cell; and (b) detecting a miRNA in a mammalian cell; and (c) detecting a miRNA in a mammalian cell;

[0098] in particular, (i) a nucleotide sequence according to SEQ ID NO: 1 to SEQ ID NO: 44 (ii) a nucleotide sequence which is a fragment of the nucleotide sequence according to (i), preferably a fragment of 1 to 12, more preferably 1 to 8, most preferably 1 to 5 or 1 to 3, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 nucleotides shorter than the nucleotide sequence according to (i); or (iii) a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the nucleotide sequence according to (i) or a fragment of the nucleotide sequence according to (ii). The level of the at least one miRNA having the formula:

[0099] In one preferred embodiment, the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:8, fragments thereof, and sequences having at least 80%, more preferably at least 85%, even more preferably at least 90%, and even more preferably at least 95% or 99% sequence identity thereto, such as 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto. In another preferred embodiment, the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, SEQ ID NO:39, fragments thereof, and sequences having at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95% or 99%, such as 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity thereto. Figure 9 shows a preferred combination of miRNAs having nucleotide sequences according to SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, and SEQ ID NO:39. It should be noted that when the levels of at least two miRNAs are determined, the miRNAs are designated as a miRNA set or signature. More preferably, the miRNA set or signature is a set or signature included in Table 2. Nucleotides according to SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, and SEQ ID NO:39 Most preferred is a combination of miRNA with a nucleic acid sequence.

[0100] The level of the at least one miRNA is associated with or correlated with response prediction.

[0101] In one embodiment, the level of the at least one miRNA is compared to a reference level of the at least one miRNA.

[0102] In particular, said reference level is the level of at least one miRNA that is empirically determined by measuring a number of reference blood samples from the subject with cancer that does not respond to cancer treatment.For example, said reference level is determined from at least 2, at least 10, at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 1000, at least 1500, at least 2000, at least 5000 reference samples from the subject with cancer that does not respond to cancer treatment.

[0103] In one preferred embodiment A level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 to SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39 to SEQ ID NO:42, SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, e.g., at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, sequence identity thereto, lower than the reference level indicates that the patient will respond to the cancer treatment; A level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:43, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, sequence identity thereto, higher than the reference level indicates that the patient will respond to the cancer treatment; A level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 to SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39 to SEQ ID NO:42, SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, equal to or greater than the reference level, indicates that the patient will not respond to the cancer treatment, or A level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:43, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, sequence identity thereto, that is equal to or lower than the reference level, indicates that the patient is not responsive to the cancer treatment.

[0104] Additionally, or alternatively, the reference level may be determined from a population of subjects suffering from a cancer that responds to said cancer treatment. The level of at least one miRNA is empirically determined by measuring a number of reference blood samples from subjects suffering from cancer that are responsive to the cancer treatment.For example, the reference level is determined from at least 2, at least 10, at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 1000, at least 1500, at least 2000, at least 5000 reference samples from subjects suffering from cancer that are responsive to the cancer treatment.

[0105] In one preferred embodiment, A level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 to SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39 to SEQ ID NO:42, SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, sequence identity thereto, above the reference level indicates that the patient will not respond to said treatment or A level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:43, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, sequence identity thereto, being below the reference level, indicates that the patient will not respond to said treatment, or a level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 to SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39 to SEQ ID NO:42, SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, e.g., at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto, that is equal to or lower than the reference level, indicates that the patient will respond to said treatment; A level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:43, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99%, e.g., at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, sequence identity thereto, that is equal to or greater than the reference level, indicates that the patient will respond to the treatment.

[0106] It can be carried out to take one reference blood sample per subject for analysis. The reference level may be an average reference level. It can be determined by measuring the reference level of the subjects and calculating its "average" value (e.g., mean, median or mode). The reference level can also be determined by a weighted sum of the levels of one or more miRNAs (preferably a weighted sum of one or more miRNAs selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 34, SEQ ID NO: 39, fragments thereof, and sequences having at least 80% sequence identity thereto). The reference blood sample is preferably from the same source (e.g., whole blood or blood fraction) as the patient's blood sample. It is further preferred that the reference level is from a control of the same sex (e.g., female or male) and / or similar age / life stage (e.g., adult or elderly) as the patient to be tested.

[0107] In the context of the present invention, said "reference level" is sometimes called "miRisk".

[0108] In an exemplary embodiment, the "reference level determined by a weighted sum of the levels of one or more RNAs" is calculated according to the following formula: miRisk=(log(miR-2115-3p RPM+1)×1.870)+(log(miR-218-5p RPM+1)×0.907)+(log(miR-224-5p RPM+1)×0.495)+(log(miR-4676-3p RPM+1)×1.309)+(log(miR-6503-5p RPM+1)×1.159)

[0109] The nucleotide sequences of miR-2115-3p, miR-218-5p, miR-224-5p, miR-4676-3p, and miR-6503-5p are shown in the attached sequence listing as SEQ ID NOs: 1, 39, 13, 7, and 34, respectively.

[0110] In certain embodiments, subjects with miRisk scores above this miRisk score threshold are non-responders and subjects with miRisk scores below this miRisk score threshold are responders to the therapy.

[0111] In certain exemplary embodiments, the miRisk score threshold is about -0.139, i.e., subjects with miRisk scores above this miRisk score threshold are non-responders, while subjects with miRisk scores below this miRisk score threshold are responders to the therapy.

[0112] Preferably, the level of the at least one miRNA is at least 0.6- or 0.7-fold, more preferably at least 0.8- or 0.9-fold, even more preferably at least 1.2-, 1.5-, or 2.0-fold, and even more preferably at least 3.0- or 4.0-fold below / above the reference level. For example, the level of the at least one miRNA is at least 0.6-fold, at least 0.7-fold, at least 0.8-fold, at least 0.9-fold, at least 1.0-fold, at least 1.1-fold, at least 1.2-fold, at least 1.3-fold, at least 1.4-fold, at least 1.5-fold, at least 1.6-fold, at least 1.7-fold, at least 1.8-fold, at least 1.9-fold, at least 2.0-fold, at least 2.1-fold, at least 2.2-fold, at least 2.3-fold, at least 2.4-fold, at least 2.5-fold, at least 2.6-fold, at least 2.7-fold, at least 2.8-fold, at least 2.9-fold, at least 3.0-fold, at least 3.1-fold, at least 3.2-fold, at least 3.3-fold, at least 3.4-fold, at least 3.5-fold, at least 3.6-fold, at least 3.7-fold, at least 3.8-fold, at least 3.9-fold, or at least 4.0-fold below / above the reference level.

[0113] By "equivalent" it is meant, as mentioned above, that the level preferably varies between 0 and <20%, e.g. 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 19.9, 19.99 or 19.999%. In this respect, "equivalent" specifically means that the detected level variations are within the precision of the measurement, which depends on the measurement method used.

[0114] In an alternative embodiment, the level of at least one miRNA is compared to an empirically determined (median) cut-off score, (median) cut-off level, or (median) threshold level. Specifically, the (median) cut-off score is determined by comparing the weighted sum of one or more miRNAs (preferably SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, SEQ ID NO:39, fragments thereof, and miRNAs having at least 80% sequence identity thereto). The cut-off score is determined by a weighted sum of one or more species of miRNAs selected from the group consisting of sequences of the following: More specifically, the (median) cut-off score allows to classify / stratify patients as responders or non-responders to cancer treatment. See above for the specific formula.

[0115] In another embodiment, the cancer treatment is selected from the group consisting of immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, anti-hormonal therapy, immunosuppressive therapy, antibody therapy, and surgical therapy.Preferably, the cancer treatment is immunotherapy or chemotherapy.

[0116] More preferably, the immunotherapy involves the administration of at least one immune checkpoint inhibitor. Even more preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and inhibitors targeting intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway. More preferably, the chemotherapy involves the administration of at least one chemotherapeutic agent. Even more preferably, the at least one chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folinic acid, antifolates, mitotic inhibitors, anthracyclines, topoisomerase inhibitors, antibodies, signal transduction inhibitors, inhibitors of angiogenesis, and inhibitors of histone deacetylase.

[0117] In one additional or alternative embodiment, the cancer is a cancer that is the subject of immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, anti-hormonal therapy, immunosuppressive therapy, antibody therapy, and / or surgical therapy.Preferably, the cancer is the subject of immunotherapy, chemotherapy, or immunochemotherapy.

[0118] More preferably, the cancer to be treated with immunotherapy is sensitive to immune checkpoint inhibition / immune checkpoint therapy. Even more preferably, the immune checkpoint inhibition involves the administration of at least one immune checkpoint inhibitor. Even more preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and inhibitors targeting intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway. Alternatively, the cancer is a PD-L1-expressing cancer. More preferably, the cancer to be treated with chemotherapy is sensitive to a chemotherapeutic agent. Even more preferably, the chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folinic acid, folate antagonists, mitotic inhibitors, anthracyclines, topoisomerase inhibitors, antibodies, signal transduction inhibitors, inhibitors of angiogenesis, and inhibitors of histone deacetylase.

[0119] Specifically, the cancer is selected from the group consisting of lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, bladder cancer, skin cancer, nasopharyngeal cancer, neuroendocrine cancer, colon cancer, urothelial cancer, liver cancer, ovarian cancer, esophageal cancer, pancreatic cancer, kidney cancer, stomach cancer, esophageal cancer, renal cancer, head and neck cancer, brain tumor, lymphatic system cancer, blood cancer, squamous cell carcinoma, laryngeal cancer, retinal cancer, prostate cancer, uterine cancer, testicular cancer, bone cancer, lymphoma, and leukemia. More specifically, the cancer is selected from the group consisting of lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, and bladder cancer, and the cancer is a target of immunotherapy.

[0120] If the patient is found to be responsive to the cancer therapy, the patient can be assigned to and subsequently treated with the cancer therapy.

[0121] In a more preferred embodiment, the method predicts the response of a patient suffering from cancer to immunotherapy, the method comprising measuring the level of at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 miRNA) in a blood sample of the patient suffering from cancer. wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto.

[0122] Preferably, the immunotherapy involves the administration of at least one immune checkpoint inhibitor. More preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0123] In an even more preferred embodiment, the method predicts the response of a patient suffering from cancer to immunotherapy involving administration of at least one immune checkpoint inhibitor, the method comprising: detecting at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or The method includes determining the level of at least one miRNA (miRNA 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 55, 56, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 112, 114, 126, 132, 148, 152, 166, 178, 180, 192, 194, 195, 196, 197, 198, 199, 200, 210, 2

[0124] In an even more preferred embodiment, the method predicts response to immunotherapy in a patient suffering from lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, or bladder cancer, the method comprising detecting at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 1 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 miRNA), wherein the at least one miRNA is at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99%, relative to SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and For example, the nucleic acid has a nucleotide sequence selected from the group consisting of sequences having at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity.

[0125] Preferably, the immunotherapy involves the administration of at least one immune checkpoint inhibitor. More preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0126] In a most preferred embodiment, the method predicts the response of a patient suffering from lung cancer, in particular non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer or bladder cancer, to immunotherapy involving administration of at least one immune checkpoint inhibitor, the method comprising detecting at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, The method includes determining the level of at least one miRNA (miRNA (s) (e.g., 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44)), wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99%, e.g., at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto.

[0127] Preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0128] The miRNA biomarkers of the present invention can be used as alternative biomarkers to the PD-L1 biomarker in immunotherapy. PD-L1 is a biomarker of response to immune checkpoint inhibitors. The experimental data of the present invention show that the miRNA biomarkers of the present invention make it possible to predict the response of patients suffering from lung cancer to immunotherapy, in particular to immune checkpoint inhibitors. The miRNA biomarkers of the present invention can also complement the PD-L1 biomarker. Central to the prediction of response to immunotherapy in the PD-1 inhibitor class is the quantification of tumor PD-L1 expression. However, still only about 30% of patients achieve a positive response. The combination of the miRNA biomarkers of the present invention with the PD-L1 biomarkers known in the prior art may improve / increase the value of 30%.

[0129] In another aspect, the present invention relates to a method for predicting response to cancer treatment in a patient suffering from cancer, comprising determining the level of at least one miRNA, wherein said at least one miRNA specifically occurs in bone marrow cells.

[0130] Myeloid cells are a subgroup of white blood cells. Myeloid cells include granulocytes, monocytes, macrophages, and dendritic cells (DC). Specifically, myeloid cells are selected from the group consisting of granulocytes, monocytes, macrophages, and dendritic cells (DC), or a combination thereof. / Mixture.

[0131] Preferably, the level of at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 miRNAs) is determined in a blood sample of a patient suffering from cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:34, SEQ ID NO:38, SEQ ID NO:41 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto. For further preferred embodiments, please refer to the first aspect of the invention.

[0132] In a second aspect, the present invention relates to an (in vitro) method of providing a prognosis to a patient suffering from cancer comprising determining the level of at least one miRNA (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 miRNA) in a blood sample of the patient suffering from cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80% sequence identity thereto.

[0133] in particular, (i) a nucleotide sequence according to SEQ ID NO:1 to SEQ ID NO:44; (ii) a nucleotide sequence which is a fragment of the nucleotide sequence according to (i), preferably 1 to 12, more preferably 1 to 8, most preferably 1 to 5 or 1 to 3 fragments thereof, e.g. a nucleotide sequence which is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 fragments shorter than the nucleotide sequence according to (i); or (iii) a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the nucleotide sequence according to (i) or a fragment of the nucleotide sequence according to (ii). The level of the at least one miRNA having the formula:

[0134] In one preferred embodiment, the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:8, fragments thereof, and sequences having at least 80%, more preferably at least 85%, even more preferably at least 90%, and even more preferably at least 95% or 99%, such as 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto. In another preferred embodiment, the at least one miRNA is a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, SEQ ID NO:39, fragments thereof, and sequences having at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95% or 99%, such as 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity thereto. 9 shows a preferred combination of miRNAs having nucleotide sequences according to SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, and SEQ ID NO:39. It should be noted that when the levels of at least two miRNAs are determined, the miRNAs are designated as a miRNA set or signature. More preferably, the miRNA set or signature is a set or signature included in Table 2. Most preferred is a combination of miRNAs having nucleotide sequences according to SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, and SEQ ID NO:39.

[0135] The level of the at least one miRNA is associated with or correlates with prognosis.

[0136] In one embodiment, the level of the at least one miRNA is compared to the reference level of the at least one miRNA.

[0137] In particular, said reference level is the level of at least one miRNA that is empirically determined by measuring a large number of reference blood samples from subjects suffering from cancer with known poor prognosis.For example, said reference level is determined from at least 2, at least 10, at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 1000, at least 1500, at least 2000, at least 5000 reference samples from subjects suffering from cancer with known poor prognosis.

[0138] In one preferred embodiment a level of at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 to SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39 to SEQ ID NO:42, SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, sequence identity thereto, lower than the reference level, indicates that the patient has a good prognosis for life; a level of at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:43, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity thereto, higher than said reference level indicates that the patient has a good prognosis for life; a level of at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 to SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39 to SEQ ID NO:42, SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, e.g., at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, sequence identity thereto, that is equal to or greater than the reference level, is indicative of a poor prognosis for the patient's life; SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:43, fragments thereof, and at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, e.g., at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, respectively, which are equal to or lower than the reference level. % sequence identity to the at least one miRNA having a nucleotide sequence selected from the group consisting of sequences having a poor prognosis for life.

[0139] Additionally or alternatively, the reference level is the level of at least one miRNA that is empirically determined by measuring a large number of reference blood samples from subjects suffering from cancer with known good prognosis.For example, the reference level is determined from at least 2, at least 10, at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 1000, at least 1500, at least 2000, at least 5000 reference samples from subjects suffering from cancer with known good prognosis.

[0140] In one preferred embodiment A level of at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 to SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39 to SEQ ID NO:42, SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, e.g., at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, sequence identity thereto, higher than the reference level is indicative of a poor prognosis for the patient; A level of at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:43, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, e.g., at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, sequence identity thereto, that is less than the reference level, is indicative of a poor prognosis for the patient's life; a level of at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 to SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39 to SEQ ID NO:42, SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, e.g. at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto, that is equal to or lower than said reference level, indicates that the patient has a good prognosis for life; or A level of at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:43, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99%, e.g., at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%, sequence identity thereto, that is equal to or greater than the reference level, indicates that the patient has a good prognosis for life.

[0141] It can be implemented to take one reference blood sample per subject for analysis. The reference level may be an average reference level. It can be determined by measuring the reference level of the subjects and calculating its "average" value (e.g., mean, median or mode). The reference level can also be determined by a weighted sum of the levels of one or more miRNAs (preferably a weighted sum of one or more miRNAs selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 34, SEQ ID NO: 39, fragments thereof, and sequences having at least 80% sequence identity thereto). The reference blood sample is a blood sample of a patient. It is preferred that the reference level is derived from the same source (e.g., whole blood or blood fraction) as the sample. It is further preferred that the reference level is from a subject of the same sex (e.g., female or male) and / or similar age / life stage (e.g., adult or elderly) as the patient being tested.

[0142] In the context of the present invention, said "reference level" is sometimes called "miRisk".

[0143] In an exemplary embodiment, the "reference level determined by a weighted sum of the levels of one or more RNAs" is calculated according to the following formula: miRisk=(log(miR-2115-3p RPM+1)×1.870)+(log(miR-218-5p RPM+1)×0.907)+(log(miR-224-5p RPM+1)×0.495)+(log(miR-4676-3p RPM+1)×1.309)+(log(miR-6503-5p RPM+1)×1.159)

[0144] The nucleotide sequences of miR-2115-3p, miR-218-5p, miR-224-5p, miR-4676-3p, and miR-6503-5p are shown in the attached sequence listing as SEQ ID NOs: 1, 39, 13, 7, and 34, respectively.

[0145] In certain embodiments, subjects with miRisk scores above this miRisk score threshold have a poor life prognosis, and subjects with miRisk scores below this miRisk score threshold have a good life prognosis.

[0146] In certain exemplary embodiments, the miRisk score is about -0.139, i.e., subjects whose miRisk score is above this miRisk score threshold have a poor life prognosis, while subjects whose miRisk score is below this miRisk score threshold have a good life prognosis.

[0147] Preferably, the level of at least one miRNA is at least 0.6- or 0.7-fold, more preferably at least 0.8- or 0.9-fold, even more preferably at least 1.2-, 1.5-, or 2.0-fold, and even more preferably at least 3.0- or 4.0-fold below / above the reference level. For example, the level of the at least one miRNA is at least 0.6-fold, at least 0.7-fold, at least 0.8-fold, at least 0.9-fold, at least 1.0-fold, at least 1.1-fold, at least 1.2-fold, at least 1.3-fold, at least 1.4-fold, at least 1.5-fold, at least 1.6-fold, at least 1.7-fold, at least 1.8-fold, at least 1.9-fold, at least 2.0-fold, at least 2.1-fold, at least 2.2-fold, at least 2.3-fold, at least 2.4-fold, at least 2.5-fold, at least 2.6-fold, at least 2.7-fold, at least 2.8-fold, at least 2.9-fold, at least 3.0-fold, at least 3.1-fold, at least 3.2-fold, at least 3.3-fold, at least 3.4-fold, at least 3.5-fold, at least 3.6-fold, at least 3.7-fold, at least 3.8-fold, at least 3.9-fold, or at least 4.0-fold below / above the reference level.

[0148] By "equivalent" it is meant, as mentioned above, that the level preferably varies between 0 and <20%, e.g. 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 19.9, 19.99 or 19.999%. In this respect, "equivalent" specifically means that the detected level variations are within the precision of the measurement, which depends on the measurement method used.

[0149] In an alternative embodiment, the level of at least one miRNA is empirically determined. The determined (median) cut-off score is compared with the (median) cut-off level or (median) threshold level. Specifically, the (median) cut-off score is determined by a weighted sum of one or more miRNAs (preferably, a weighted sum of one or more miRNAs selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 34, SEQ ID NO: 39, fragments thereof, and sequences having at least 80% sequence identity thereto). More specifically, the (median) cut-off score can classify patients as having good or bad life prognosis. See above for specific formulas.

[0150] Specifically, a good life prognosis is associated with a high possibility / probability of surviving for a certain period of time, or a bad life prognosis is associated with a low possibility / probability of surviving for a certain period of time.

[0151] in particular A patient with a good prognosis has a possibility / probability of more than 50%, preferably more than 60%, more preferably more than 70%, even more preferably more than 80%, even more preferably more than 90%, or most preferably more than 95% to survive for a certain period of time, while a patient with a poor prognosis has a probability of 50% or less, preferably 40% or less, more preferably 30% or less, even more preferably 20% or less, even more preferably 10% or less, and most preferably 5% or less to survive for a certain period of time.

[0152] More specifically, the fixed period is a period of (at least / at most) 3 months, 6 months, 9 months, 12 months (1 year), 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years.

[0153] For example, a patient with a good prognosis has a chance / probability of more than 50%, preferably more than 60%, more preferably more than 70%, even more preferably more than 80%, even more preferably more than 90%, or most preferably more than 95%, to survive for (at least) 3 months, 6 months, 9 months, 12 months (1 year), 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years, or a patient with a poor prognosis has a chance / probability of less than 50%, preferably less than 40%, more preferably less than 30%, even more preferably less than 20%, even more preferably less than 10%, and most preferably less than 5%, to survive for (at most) 3 months, 6 months, 9 months, 12 months (1 year), 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years.

[0154] Prognosis can be defined as predicted survival at 2 or 5 years of follow-up. For example, patients with good prognosis are still alive at 2 or 5 years of follow-up, while patients with poor prognosis are no longer alive at 2 or 5 years of follow-up.

[0155] In another embodiment, the patient is a patient who is going to be administered, is administered or has been administered cancer treatment.Preferably, the patient is an untreated cancer patient.If the patient is found to have a good life prognosis, the patient can be assigned to the cancer treatment and then treated with the cancer treatment.Preferably, the cancer treatment is selected from the group consisting of immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, antihormonal therapy, immunosuppressive therapy, antibody therapy and surgical therapy.More preferably, the cancer treatment is immunotherapy or chemotherapy.

[0156] Even more preferably, the immunotherapy involves administration of the at least one immune checkpoint inhibitor.Even more preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and endogenous checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor that targets PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0157] Even more preferably, the chemotherapy involves the administration of at least one chemotherapeutic agent, even more preferably still, the at least one chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folinic acid, antifolates, mitotic inhibitors, anthracyclines, topoisomerase inhibitors, antibodies, signal transduction inhibitors, inhibitors of angiogenesis, and inhibitors of histone deacetylase.

[0158] In one additional or alternative embodiment, the cancer is a cancer that is the subject of immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, anti-hormonal therapy, immunosuppressive therapy, antibody therapy, and / or surgical therapy.Preferably, the cancer is the subject of immunotherapy, chemotherapy, or immunochemotherapy.

[0159] More preferably, the cancer to be treated with immunotherapy is susceptible to immune checkpoint inhibition / immune checkpoint therapy. Even more preferably, the immune checkpoint inhibition involves administration of said at least one immune checkpoint inhibitor. Even more preferably, said at least one immune checkpoint inhibitor is selected from the group consisting of PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and inhibitors targeting intrinsic checkpoint blockade. Specifically, said at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway. Alternatively, the cancer is a PD-L1 expressing cancer.

[0160] More preferably, the cancer to be treated with chemotherapy is sensitive to the chemotherapeutic agent. Even more preferably, the chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folinic acid, antifolates, mitotic inhibitors, anthracyclines, topoisomerase inhibitors, antibodies, signal transduction inhibitors, inhibitors of angiogenesis, and inhibitors of histone deacetylase.

[0161] Specifically, the cancer is selected from the group consisting of lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, bladder cancer, skin cancer, nasopharyngeal cancer, neuroendocrine cancer, colon cancer, urothelial cancer, liver cancer, ovarian cancer, esophageal cancer, pancreatic cancer, kidney cancer, stomach cancer, esophageal cancer, renal cancer, head and neck cancer, brain tumor, lymphatic system cancer, blood cancer, squamous cell carcinoma, laryngeal cancer, retinal cancer, prostate cancer, uterine cancer, testicular cancer, bone cancer, lymphoma, and leukemia. More specifically, the cancer is selected from the group consisting of lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, and bladder cancer. The cancer is a target of immunotherapy.

[0162] In a more preferred embodiment, the method provides a prognosis for a patient suffering from cancer, the method comprising determining the level of at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 miRNA) in a blood sample of the patient suffering from cancer, wherein the at least one miRNA is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, e.g., at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto. having a nucleotide sequence corresponding to Here, the patient is one who will be receiving, is receiving, or has received immunotherapy.

[0163] Preferably, the immunotherapy involves the administration of at least one immune checkpoint inhibitor. More preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0164] In an even more preferred embodiment, the method provides a prognosis for a patient suffering from cancer, the method comprising determining the level of at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 miRNA) in a blood sample of the patient suffering from cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto; Here, the patient is one who will be administered, is being administered, or has been administered immunotherapy involving administration of at least one immune checkpoint inhibitor.

[0165] Preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0166] In an even more preferred embodiment, the method provides a prognosis for a patient suffering from lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, or bladder cancer, said method comprising determining the level of at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 miRNA) in a blood sample of the patient suffering from lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, or bladder cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto; Here, the patient is a patient who is to be administered, is being administered, or has been administered immunotherapy. Preferably, the immunotherapy involves administration of at least one immune checkpoint inhibitor. More preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and inhibitors targeting endogenous checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0167] In a most preferred embodiment, the method provides a prognosis for survival to a patient suffering from lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, or bladder cancer, and the method comprises detecting at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, , 37, 38, 39, 40, 41, 42, 43, or 44 miRNA), wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto; Here, the patient is one who will be administered, is being administered, or has been administered immunotherapy involving administration of at least one immune checkpoint inhibitor.

[0168] Preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0169] The miRNA biomarker of the present invention can be used as an alternative biomarker to PD-L1 biomarker in immunotherapy.The experimental data of the present invention show that the miRNA biomarker of the present invention can make the life prognosis of patients suffering from lung cancer who have received immunotherapy, especially immune checkpoint inhibitors.The miRNA biomarker of the present invention can also complement the PD-L1 biomarker.

[0170] In another aspect, the present invention relates to a method for providing a prognosis to a patient suffering from cancer comprising determining the level of at least one miRNA, wherein at least the miRNA occurs specifically / exclusively in bone marrow cells.

[0171] Myeloid cells are a subgroup of white blood cells. Myeloid cells include granulocytes, monocytes, macrophages, and dendritic cells (DCs). Specifically, myeloid cells are selected from the group consisting of granulocytes, monocytes, macrophages, and dendritic cells (DCs), or a combination / mixture thereof.

[0172] Preferably, the level of at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 miRNAs) is determined in a blood sample of a patient suffering from cancer, wherein the level of the at least one miRNA is at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95% or 99%, e.g., at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 7 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity. For further preferred embodiments, see the second aspect of the invention.

[0173] In a third aspect, the present invention relates to an (in vitro) method for predicting side effects of cancer treatment in a patient, comprising determining the level of at least one miRNA in a blood sample of a patient suffering from cancer, The at least one miRNA (e.g., miRNA 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44) is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto.

[0174] in particular, (i) a nucleotide sequence according to SEQ ID NO:1 to SEQ ID NO:44, (ii) a nucleotide sequence which is a fragment of the nucleotide sequence according to (i), preferably a fragment which is 1 to 12, more preferably 1 to 8, most preferably 1 to 5 or 1 to 3, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, shorter than the nucleotide sequence according to (i); or (iv) a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the nucleotide sequence according to (i) or a fragment of the nucleotide sequence according to (ii); The level of at least one miRNA having the formula:

[0175] In a preferred embodiment, the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:8, fragments thereof, and sequences having at least 80%, more preferably at least 85%, even more preferably at least 90%, and even more preferably at least 95% or 99% sequence identity thereto, such as 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto. In another preferred embodiment, the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, SEQ ID NO:39, fragments thereof, and sequences having at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95% or 99% sequence identity thereto (e.g., 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%). Figure 9 shows a preferred combination of miRNAs having nucleotide sequences according to SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, and SEQ ID NO:39. It should be noted that when the levels of at least two miRNAs are determined, the miRNAs are referred to as a miRNA set or signature. More preferably, the miRNA set or signature is a set or signature included in Table 2. Most preferred is a combination of miRNAs having nucleotide sequences according to SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, and SEQ ID NO:39.

[0176] The level of the at least one miRNA is associated with the likelihood of experiencing a side effect during cancer treatment.

[0177] In one embodiment, the level of at least one miRNA is compared with an empirically determined (median) cut-off score, (median) cut-off level, or (median) threshold level.Specifically, the (median) cut-off score is determined by the weighted sum of the levels of one or more miRNAs (preferably the weighted sum of one or more miRNAs selected from the group consisting of SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, SEQ ID NO:39, fragments thereof, and sequences having at least 80% sequence identity thereto).More specifically, the (median) cut-off score allows to classify patients into those who do not suffer from side effects or those who suffer from side effects.

[0178] In the context of the present invention, said "reference level" or "cut-off score" may be referred to as "miRisk".

[0179] In an exemplary embodiment, the "weighted sum of the levels of one or more RNAs" is calculated according to the following formula: miRisk=(log(miR-2115-3p RPM+1)×1.870)+(log(miR-218-5p RPM+1)×0.907)+(log(miR-224-5p RPM+1)×0.495)+(log(miR-4676-3p RPM+1)×1.309)+(log(miR-6503-5p RPM+1)×1.159)

[0180] The nucleotide sequences of miR-2115-3p, miR-218-5p, miR-224-5p, miR-4676-3p, and miR-6503-5p are shown in the attached sequence listing as SEQ ID NOs: 1, 39, 13, 7, and 34, respectively.

[0181] In certain embodiments, this miRisk score threshold makes it possible to classify patients as those not suffering from a side effect or those suffering from a side effect.

[0182] In certain exemplary embodiments, the miRisk score threshold is about −0.139; that is, this miRisk score threshold allows for classification of patients as those not suffering from a side effect or those suffering from a side effect. In particular, the side effect is an immune-related adverse event. More particularly, the side effect, in particular the immune-related adverse event, is selected from the group consisting of endocrinopathy, dermatitis, colitis, polymyaglia rheumatica (PMR), hypophysitis, myositis, thyroiditis, pneumonitis, polyarthritis, hepatitis, serositis, hypothyroidism, arthritis, synovialitides, and psoriasis.

[0183] In another embodiment, the cancer treatment is selected from the group consisting of immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, anti-hormonal therapy, immunosuppressive therapy, antibody therapy, and surgical therapy.Preferably, the cancer treatment is immunotherapy or chemotherapy.

[0184] More preferably, the immunotherapy involves the administration of at least one immune checkpoint inhibitor. Even more preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0185] More preferably, the at least one chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folinic acid, antifolates, mitotic inhibitors, anthracyclines, topoisomerase inhibitors, antibodies, signal transduction inhibitors, inhibitors of angiogenesis, and inhibitors of histone deacetylase.

[0186] The patient is a patient suffering from cancer. In one further or alternative embodiment, the cancer is a cancer that is the subject of immunotherapy, chemotherapy, radiotherapy, vaccination therapy, stem cell therapy, antihormonal therapy, immunosuppressive therapy, antibody therapy, and / or surgical therapy. Preferably, the cancer is the subject of immunotherapy, chemotherapy or immunochemotherapy. More preferably, the cancer that is the subject of immunotherapy is sensitive to immune checkpoint inhibition / immune checkpoint therapy. Even more preferably, the immune checkpoint inhibition involves the administration of at least one immune checkpoint inhibitor. Even more preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and inhibitors targeting intrinsic checkpoint blockade. In particular, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway. Alternatively, the cancer is a PD-L1 expressing cancer. Alternatively, the cancer is a PD-L1 expressing cancer.

[0187] More preferably, the cancer to be treated with chemotherapy is sensitive to the chemotherapeutic agent. Even more preferably, the chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folinic acid, antifolates, mitotic inhibitors, anthracyclines, topoisomerase inhibitors, antibodies, signal transduction inhibitors, inhibitors of angiogenesis, and inhibitors of histone deacetylase.

[0188] Specifically, the cancer is selected from the group consisting of lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, bladder cancer, skin cancer, nasopharyngeal cancer, neuroendocrine cancer, colon cancer, urothelial cancer, liver cancer, ovarian cancer, esophageal cancer, pancreatic cancer, kidney cancer, stomach cancer, esophageal cancer, renal cancer, head and neck cancer, brain tumor, lymphatic system cancer, blood cancer, squamous cell carcinoma, laryngeal cancer, retinal cancer, prostate cancer, uterine cancer, testicular cancer, bone cancer, lymphoma, and leukemia. More specifically, the cancer is selected from the group consisting of lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, and bladder cancer, which cancer is amenable to immunotherapy.

[0189] In a more preferred embodiment, the method predicts side effects of immunotherapy in a patient, the method comprising determining the level of at least one miRNA in a blood sample of a patient suffering from cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto. Preferably, the immunotherapy involves administration of at least one immune checkpoint inhibitor. More preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and inhibitors targeting intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor that targets PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0190] In an even more preferred embodiment, the method predicts side effects of immunotherapy associated with administration of at least one immune checkpoint inhibitor to a patient, the method comprising detecting at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 miRNA) in a blood sample of the patient suffering from cancer. The method includes determining the level of at least one miRNA (iRNA), wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99%, e.g., at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto.

[0191] Preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0192] In an even more preferred embodiment, the method is for predicting side effects of immunotherapy in a patient, the method comprising determining the level of at least one miRNA in a blood sample of a patient suffering from lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer or bladder cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto.

[0193] Preferably, the immunotherapy involves the administration of at least one immune checkpoint inhibitor. More preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0194] In one most preferred embodiment, the method predicts side effects in immunotherapy associated with administration of at least one immune checkpoint inhibitor in a patient, the method comprising determining the level of at least one miRNA in a blood sample of a patient suffering from lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer or bladder cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto.

[0195] Preferably, the at least one immune checkpoint inhibitor is selected from PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and the intrinsic checkpoint inhibitor. In one embodiment, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors that target PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0196] The above-mentioned side effects are particularly immune-related adverse events. More specifically, the side effects, particularly immune-related adverse events, are selected from the group consisting of endocrinopathy, dermatitis, colitis, polymyalgia rheumatica (PMR), hypophysitis, myositis, thyroiditis, pneumonitis, polyarthritis, hepatitis, serositis, hypothyroidism, arthritis, synovialitides, and psoriasis.

[0197] In another aspect, the present invention relates to a method for predicting side effects in a patient's cancer treatment comprising determining the level of at least one miRNA, wherein at least one miRNA occurs specifically / exclusively in bone marrow cells.

[0198] Myeloid cells are a subgroup of white blood cells and include granulocytes, monocytes, macrophages, and dendritic cells (DCs). Specifically, the myeloid cells are selected from the group consisting of granulocytes, monocytes, macrophages, and dendritic cells (DCs), or a combination / mixture thereof.

[0199] Preferably, the level of at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 miRNAs) is determined in a blood sample of a patient suffering from cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:34, SEQ ID NO:38, SEQ ID NO:41 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto. For further preferred embodiments, see the third aspect of the invention.

[0200] In a fourth aspect, the present invention relates to an (in vitro) method for monitoring a patient suffering from cancer, comprising determining the level of at least one miRNA in a blood sample of said patient, The at least one miRNA (e.g., miRNA 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44) may be selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto. The method makes it possible to determine the course of cancer in a patient.

[0201] in particular, (i) a nucleotide sequence according to SEQ ID NO:1 to SEQ ID NO:44; (ii) a nucleotide sequence which is a fragment of the nucleotide sequence of (i), preferably 1 to 12, more preferably 1 to 8, most preferably 1 to 2, more ... a nucleotide sequence which is a fragment, preferably 1 to 5 or 1 to 3, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 nucleotides, or (v) a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the nucleotide sequence according to (i) or a fragment of the nucleotide sequence according to (ii); The level of at least one miRNA having the formula:

[0202] In one preferred embodiment, the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:8, fragments thereof, and sequences having at least 80%, more preferably at least 85%, even more preferably at least 90%, and even more preferably at least 95% or 99% sequence identity thereto, such as 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto. In another preferred embodiment, the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, SEQ ID NO:39, fragments thereof, and sequences having at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95% or 99%, such as 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity thereto. Figure 9 shows a preferred combination of miRNAs having nucleotide sequences according to SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, and SEQ ID NO:39. It should be noted that when the levels of at least two miRNAs are determined, the miRNAs are referred to as a miRNA set or signature. More preferably, the miRNA set or signature is a set or signature included in Table 2. Most preferred are combinations of miRNAs having nucleotide sequences according to SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, and SEQ ID NO:39.

[0203] In one embodiment, the level of the at least one miRNA is compared to the reference level of the at least one miRNA.

[0204] This comparison can determine the progress of the cancer in the patient: whether the cancer gets worse in the patient, whether the cancer is not getting worse / stable in the patient, or whether the cancer is improving in the patient.

[0205] Said reference level can be any level that allows to determine the progress of cancer in a patient.It can be obtained from a (control) subject (i.e., a subject different from the tested patient, such as a healthy subject and / or a subject with cancer) or from the same patient.In the latter case, the individual can be retested for cancer, for example, in the form of longitudinal monitoring.It can be determined that the individual is still suffering from cancer disease or no longer suffering from cancer disease.

[0206] In the context of the present invention, said "reference level" may be referred to as "miRisk".

[0207] In an exemplary embodiment, the reference level may be calculated according to the following formula: miRisk=(log(miR-2115-3p RPM+1)×1.870)+(log(miR-218-5p RPM+1)×0.907)+(log(miR-22 4-5p RPM+1)×0.495)+(log(miR-4676-3p RPM+1)×1.309)+(log(miR-6503-5p RPM+1)×1.159).

[0208] The nucleotide sequences of miR-2115-3p, miR-218-5p, miR-224-5p, miR-4676-3p, and miR-6503-5p are shown in the attached sequence listing as SEQ ID NOs: 1, 39, 13, 7, and 34, respectively.

[0209] In one particular embodiment, this miRisk score threshold may make it possible to determine whether the cancer worsens in a patient, whether the cancer does not worsen / stable in a patient, or whether the cancer improves in a patient.

[0210] In certain exemplary embodiments, the miRisk score threshold is about -0.139. This miRisk score threshold may allow for determining whether the cancer is worsening in a patient, whether the cancer is not worsening / stable in a patient, or whether the cancer is improving in a patient.

[0211] In particular, said reference level is the level of at least one miRNA that is empirically determined by measuring a number of reference blood samples from subjects suffering from cancer.For example, said reference level is determined from at least 2, at least 10, at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 1000, at least 1500, at least 2000, at least 5000 reference samples from subjects suffering from cancer.

[0212] In another embodiment, said determination comprises determining the level of at least one miRNA in the blood sample of the patient suffering from cancer at a first time point and in at least one additional blood sample (of the same patient) at a later time point, and comparing said levels determined at different time points.This comparison can determine the progress of cancer in the patient.Can determine whether cancer worsens in the patient, whether cancer does not worsen / stable in the patient, or whether cancer improves in the patient.

[0213] The period between the first time point and the later time point is preferably at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days (1 week), at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 1 month, or at least 2 months.For example, the patient may be examined periodically, for example, every day or once a week.The patient may be (re)examined at the second, third, fourth, fifth, sixth, seventh, eighth, nineth, or tenth time points (first time point and further time points).

[0214] In addition to determining the progress of cancer in a patient, the patient's cancer treatment can be monitored. Thus, in one preferred embodiment, the patient is undergoing, has undergone, or has undergone said cancer treatment.

[0215] For example, the patient may receive treatment during the entire determination / monitoring process (e.g., administration of a drug or agent), or may receive treatment before, at, or after a first time point (e.g., administration of a drug or agent) and may be re-examined at a later time point. In particular, the first time point may be before the start of treatment and the later time point may be during and / or after treatment. If the treatment involves administration of a drug or agent and the patient responds to the treatment, the administration of the drug or agent may be continued, the dose of the drug or agent may be reduced, or the administration of the drug or agent may be stopped. If the treatment involves administration of a drug or agent and the patient does not respond to the treatment, the dose of the drug or agent may be increased, the drug or agent may be changed, Or the treatment modality may be changed, for example, changing immunotherapy to chemotherapy. The drug or agent may be an immune checkpoint inhibitor or a chemotherapeutic agent.

[0216] Preferably, the cancer treatment is selected from the group consisting of immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, anti-hormonal therapy, immunosuppressive therapy, antibody therapy, and surgical therapy. More preferably, the cancer treatment is immunotherapy or chemotherapy.

[0217] Even more preferably, the immunotherapy involves administration of at least one immune checkpoint inhibitor. Even more preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and intrinsic checkpoint blockade. In particular, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0218] Even more preferably, the chemotherapy involves the administration of at least one chemotherapeutic agent. Even more preferably, the at least one chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folinic acid, antifolates, mitotic inhibitors, anthracyclines, topoisomerase inhibitors, antibodies, signal transduction inhibitors, inhibitors of angiogenesis, and inhibitors of histone deacetylase.

[0219] In one additional or alternative embodiment, the cancer is a cancer that is the subject of immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, anti-hormonal therapy, immunosuppressive therapy, antibody therapy, and / or surgical therapy.Preferably, the cancer is the subject of immunotherapy, chemotherapy, or immunochemotherapy.

[0220] More preferably, the cancer to be treated with immunotherapy is sensitive to immune checkpoint inhibition / immune checkpoint therapy. Even more preferably, the immune checkpoint inhibition involves the administration of at least one immune checkpoint inhibitor. Even more preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and intrinsic checkpoint blockade. In particular, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway. Alternatively, the cancer is a PD-L1 expressing cancer.

[0221] More preferably, the cancer to be treated with chemotherapy is sensitive to the chemotherapeutic agent. Even more preferably, the chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folinic acid, antifolates, mitotic inhibitors, anthracyclines, topoisomerase inhibitors, antibodies, signal transduction inhibitors, inhibitors of angiogenesis, and inhibitors of histone deacetylase.

[0222] Specifically, the cancer is selected from the group consisting of lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, bladder cancer, skin cancer, nasopharyngeal cancer, neuroendocrine cancer, colon cancer, urothelial cancer, liver cancer, ovarian cancer, esophageal cancer, pancreatic cancer, kidney cancer, stomach cancer, esophageal cancer, renal cancer, head and neck cancer, brain tumor, lymphatic system cancer, blood cancer, squamous cell carcinoma, laryngeal cancer, retinal cancer, prostate cancer, uterine cancer, testicular cancer, bone cancer, lymphoma, and leukemia. More specifically, the cancer is selected from the group consisting of lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, and bladder cancer, which cancer is amenable to immunotherapy.

[0223] In a more preferred embodiment, the method is for monitoring a patient suffering from cancer, the method comprising: (i) determining the level of at least one miRNA in a blood sample of a patient suffering from cancer at a first time point and the level of at least one miRNA in at least one further blood sample (of the same patient) at a later time point; and (ii) comparing said levels determined at different time points. Including, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity thereto; and wherein the patient is undergoing, has undergone, or has undergone immunotherapy for said cancer.

[0224] Preferably, the immunotherapy involves the administration of at least one immune checkpoint inhibitor. More preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0225] In an even more preferred embodiment, the method is for monitoring a patient suffering from cancer, the method comprising: (i) determining the level of at least one miRNA in a blood sample of a patient suffering from cancer at a first time point and the level of at least one miRNA in at least one further blood sample (of the same patient) at a later time point; and (ii) comparing said levels determined at different time points. Including, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity thereto; and wherein the patient is undergoing, has undergone, or has undergone immunotherapy for said cancer in conjunction with administration of at least one immune checkpoint inhibitor.

[0226] Preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0227] In an even more preferred embodiment, the method is for monitoring a patient suffering from lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer or bladder cancer, the method comprising: (i) lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer or determining the level of at least one miRNA in a blood sample of a patient suffering from bladder cancer at a first time point and determining the level of at least one miRNA in at least one further blood sample (of the same patient) at a subsequent time point; and (ii) comparing said levels determined at different time points. Including, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity thereto; and wherein the patient is undergoing, has undergone, or has undergone immunotherapy for said cancer.

[0228] Preferably, the immunotherapy involves the administration of at least one immune checkpoint inhibitor. More preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0229] In a most preferred embodiment, the method is for monitoring a patient suffering from lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer or bladder cancer, the method comprising: (i) determining the level of at least one miRNA in a blood sample of a patient suffering from lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer or bladder cancer, at a first time point and determining the level of at least one miRNA in at least one further blood sample (of the same patient) at a subsequent time point; and (ii) comparing said levels determined at different time points. Including, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity thereto; and Here, the patient is undergoing, has undergone, or has undergone immunotherapy involving administration of at least one immune checkpoint inhibitor for the cancer.

[0230] Preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0231] Thus, the above methods allow for continuous assessment of disease status for evidence of efficacy of cancer treatment.

[0232] In another aspect, the present invention relates to a method for monitoring a patient suffering from cancer comprising determining the level of at least one miRNA, wherein at least the miRNA occurs specifically / exclusively in myeloid cells. Myeloid cells are a subgroup of white blood cells and include granulocytes, monocytes, macrophages, and dendritic cells (DCs). Specifically, the myeloid cells are selected from the group consisting of granulocytes, monocytes, macrophages, and dendritic cells (DCs), or a combination thereof. Preferably, the level of at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 miRNAs) is determined in a blood sample of a patient suffering from cancer, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:34, SEQ ID NO:38, SEQ ID NO:41 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto. For further preferred embodiments, see the fourth aspect of the invention.

[0233] In the methods of the first to fourth aspects, the blood sample is preferably whole blood or a blood fraction. In particular, the blood fraction is selected from the group consisting of a blood cell fraction and plasma or serum. More preferably, the blood fraction is selected from the group consisting of a blood cell fraction, plasma, and serum. The blood cell fraction may comprise red blood cells, white blood cells, and / or platelets. Even more preferably, the blood cell fraction is a white blood cell fraction. In particular, the white blood cells are myeloid cells and / or lymphocytes. More particularly, the myeloid cells are selected from the group consisting of granulocytes, monocytes, macrophages, and dendritic cells (DC), or a combination thereof.

[0234] In the methods of the first to fourth aspects, the level is preferably determined by sequencing, more preferably next generation sequencing, nucleic acid hybridization, nucleic acid amplification, polymerase extension, mass spectrometry, or any combination thereof. In particular, the level is an expression level.

[0235] In a fifth aspect, the present invention provides a method for producing a method for treating a cancer cell comprising: (i) identifying a patient who responds to cancer treatment by carrying out the method according to the first aspect, identifying a patient with a good prognosis by carrying out the method according to the second aspect, or identifying a patient who does not experience side effects from cancer treatment by carrying out the method according to the third aspect; (ii) allocating the patient to a (relevant) cancer treatment; The present invention relates to an (in vitro) method for determining whether to treat a patient suffering from cancer, comprising:

[0236] In one embodiment, the cancer treatment is selected from the group consisting of immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, anti-hormonal therapy, immunosuppressive therapy, antibody therapy, and surgical therapy.

[0237] Preferably, the cancer treatment is immunotherapy or chemotherapy. More preferably, the immunotherapy involves the administration of at least one immune checkpoint inhibitor. Even more preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0238] More preferably, the at least one chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folinic acid, antifolates, mitotic inhibitors, anthracyclines, topoisomerase inhibitors, antibodies, signal transduction inhibitors, inhibitors of angiogenesis, and inhibitors of histone deacetylase.

[0239] In one additional or alternative embodiment, the cancer is a cancer that is the subject of immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, anti-hormonal therapy, immunosuppressive therapy, antibody therapy, and / or surgical therapy.Preferably, the cancer is the subject of immunotherapy, chemotherapy, or immunochemotherapy.

[0240] More preferably, the cancer to be treated with immunotherapy is sensitive to immune checkpoint inhibition / immune checkpoint therapy. Even more preferably, the immune checkpoint inhibition involves the administration of at least one immune checkpoint inhibitor. Even more preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and intrinsic checkpoint blockade. In particular, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway. Alternatively, the cancer is a PD-L1 expressing cancer.

[0241] More preferably, the cancer to be treated with chemotherapy is sensitive to the chemotherapeutic agent. Even more preferably, the chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folinic acid, antifolates, mitotic inhibitors, anthracyclines, topoisomerase inhibitors, antibodies, signal transduction inhibitors, inhibitors of angiogenesis, and inhibitors of histone deacetylase.

[0242] Specifically, the cancer is selected from the group consisting of lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, bladder cancer, skin cancer, nasopharyngeal cancer, neuroendocrine cancer, colon cancer, urothelial cancer, liver cancer, ovarian cancer, esophageal cancer, pancreatic cancer, kidney cancer, stomach cancer, esophageal cancer, renal cancer, head and neck cancer, brain tumor, lymphatic system cancer, blood cancer, squamous cell carcinoma, laryngeal cancer, retinal cancer, prostate cancer, uterine cancer, testicular cancer, bone cancer, lymphoma, and leukemia. More specifically, the cancer is selected from the group consisting of lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, and bladder cancer, which cancer is amenable to immunotherapy.

[0243] After a patient is assigned to a cancer therapy, the patient is eventually treated with the cancer therapy.

[0244] In a more preferred embodiment, the method is for determining whether to treat a patient suffering from cancer, the method comprising: (i) identifying a patient who responds to immunotherapy by carrying out the method according to the first aspect, identifying a patient with a good prognosis by carrying out the method according to the second aspect, or identifying a patient who does not experience side effects in immunotherapy by carrying out the method according to the third aspect; (ii) allocating the patient to the immunotherapy (of interest). Includes. Preferably, the immunotherapy involves the administration of at least one immune checkpoint inhibitor. More preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and endogenous checkpoint blockade. In particular, at least one One type of immune checkpoint inhibitor is an inhibitor that targets PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0245] In an even more preferred embodiment, the method is for determining whether to treat a patient suffering from cancer, the method comprising: (i) identifying a patient as a patient who responds to immunotherapy involving administration of at least one immune checkpoint inhibitor by carrying out the method according to the first aspect, identifying a patient as a patient who has a good prognosis by carrying out the method according to the second aspect, or identifying a patient as a patient who does not experience side effects in immunotherapy involving administration of at least one immune checkpoint inhibitor by carrying out the method according to the third aspect; (ii) allocating the patient to the immunotherapy; Includes. Preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0246] In an even more preferred embodiment, the method is for determining whether to treat a patient suffering from lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, or bladder cancer, the method comprising: (i) identifying a patient who responds to immunotherapy by carrying out the method according to the first aspect, identifying a patient with a good prognosis by carrying out the method according to the second aspect, or identifying a patient who does not experience side effects in immunotherapy by carrying out the method according to the third aspect; (ii) allocating the patient to the immunotherapy; Includes. Preferably, the immunotherapy involves the administration of at least one immune checkpoint inhibitor. More preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0247] In a most preferred embodiment, the method is for determining whether to treat a patient suffering from lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, or bladder cancer, the method comprising: (i) identifying a patient who responds to immunotherapy involving administration of at least one immune checkpoint inhibitor by carrying out the method according to the first aspect, or identifying a patient who does not experience side effects in immunotherapy involving administration of at least one immune checkpoint inhibitor by carrying out the method according to the third aspect; and (ii) assigning the patient to said immunotherapy; Includes. Preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0248] In a sixth aspect, the present invention provides a method for predicting the response of a patient suffering from cancer to a cancer treatment, comprising the steps of: detecting at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 miRNA), or a polynucleotide allowing the detection of said at least one miRNA. For (in vitro) uses, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto.

[0249] In a seventh aspect, the present invention relates to the (in vitro) use of at least one miRNA (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 miRNA), or a polynucleotide allowing the detection of said at least one miRNA, for providing a prognosis for a patient suffering from cancer, wherein , 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44) has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, a fragment thereof, and a sequence having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto.

[0250] In an eighth aspect, the present invention provides an in vivo assay for predicting side effects in a patient's cancer treatment, comprising at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 miRNA) or a polynucleotide enabling detection of said at least one miRNA. For the use of the present invention, the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto.

[0251] In a ninth aspect, the present invention relates to the (in vitro) use of at least one miRNA (e.g. miRNA 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43 or 44) or a polynucleotide allowing the detection of said at least one miRNA, for monitoring a patient suffering from cancer, wherein said at least one miRNA is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof and a sequence similar to at least 80%, preferably at least 85%, more preferably at least 85%. Preferably, the nucleic acid has a nucleotide sequence selected from the group consisting of sequences having at least 90%, most preferably at least 95% or 99%, for example at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the nucleic acid.

[0252] In a tenth aspect, the present invention provides a method for determining whether to treat a patient suffering from cancer, comprising the step of detecting at least one miRNA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 miRNA), or a polynucleotide allowing the detection of said at least one miRNA. For (in vitro) uses, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:44, fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto.

[0253] With respect to the seventh to tenth aspects the following applies: In one embodiment, the cancer treatment is selected from the group consisting of immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, anti-hormonal therapy, immunosuppressive therapy, antibody therapy, and surgical therapy.Preferably, the cancer treatment is immunotherapy or chemotherapy. More preferably, the immunotherapy involves the administration of at least one immune checkpoint inhibitor. Even more preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and intrinsic checkpoint blockade. Specifically, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0254] More preferably, the chemotherapy involves the administration of at least one chemotherapeutic agent. Even more preferably, the at least one chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folinic acid, antifolates, mitotic inhibitors, anthracyclines, topoisomerase inhibitors, antibodies, signal transduction inhibitors, inhibitors of angiogenesis, and inhibitors of histone deacetylase.

[0255] In one additional or alternative embodiment, the cancer is a cancer that is the subject of immunotherapy, chemotherapy, radiation therapy, vaccination therapy, stem cell therapy, anti-hormonal therapy, immunosuppressive therapy, antibody therapy, and / or surgical therapy.Preferably, the cancer is the subject of immunotherapy, chemotherapy, or immunochemotherapy.

[0256] More preferably, the cancer to be treated with immunotherapy is sensitive to immune checkpoint inhibition / immune checkpoint therapy. Even more preferably, the immune checkpoint inhibition involves the administration of at least one immune checkpoint inhibitor. Even more preferably, the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73 and intrinsic checkpoint blockade. In particular, the at least one immune checkpoint inhibitor is an inhibitor targeting PD-1 / PD-L1 or the PD-1 / PD-L1 pathway. Alternatively, the cancer is a PD-L1 expressing cancer.

[0257] More preferably, the cancer to be treated with chemotherapy is sensitive to the chemotherapeutic agent. More preferably, the chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folinic acid, antifolates, mitotic inhibitors, anthracyclines, topoisomerase inhibitors, antibodies, signal transduction inhibitors, inhibitors of angiogenesis, and inhibitors of histone deacetylase.

[0258] Specifically, the cancer is selected from the group consisting of lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, bladder cancer, skin cancer, nasopharyngeal cancer, neuroendocrine cancer, colon cancer, urothelial cancer, liver cancer, ovarian cancer, esophageal cancer, pancreatic cancer, kidney cancer, stomach cancer, esophageal cancer, renal cancer, head and neck cancer, brain tumor, lymphatic system cancer, blood cancer, squamous cell carcinoma, laryngeal cancer, retinal cancer, prostate cancer, uterine cancer, testicular cancer, bone cancer, lymphoma, and leukemia. More specifically, the cancer is selected from the group consisting of lung cancer, preferably non-small cell lung cancer (NSCLC), breast cancer, cervical cancer, gastric cancer, and bladder cancer, which cancer is amenable to immunotherapy.

[0259] The polynucleotide can be a primer (eg, a primer probe) or a polynucleotide probe.

[0260] Preferably, the (level of) at least one miRNA is detected / determined in a blood sample of a patient suffering from cancer. For preferred embodiments of the blood sample reference is made to the first to fourth aspects of the invention.

[0261] In an eleventh aspect, the present invention relates to a kit (for (in vitro) use) for predicting a response to cancer treatment in a patient suffering from cancer, for providing a prognosis for a patient suffering from cancer, for predicting side effects in a patient's cancer treatment, for monitoring a patient suffering from cancer or for deciding whether to treat a patient suffering from cancer, the kit comprising means for determining the level of at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof and sequences having at least 80% sequence identity thereto.

[0262] Specifically, the kit of the present invention comprises: (i) a nucleotide sequence according to SEQ ID NO:1 to SEQ ID NO:44; (ii) a nucleotide sequence which is a fragment of the nucleotide sequence according to (i), preferably a fragment of 1 to 12, more preferably 1 to 8, most preferably 1 to 5 or 1 to 3, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 nucleotides shorter than the nucleotide sequence according to (i); or (vi) a nucleotide sequence having at least 80%, preferably at least 85%, more preferably at least 90%, most preferably at least 95% or 99%, such as at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the nucleotide sequence according to (i) or the nucleotide sequence fragment according to (ii), The method includes determining the level of at least one miRNA having the formula: In one preferred embodiment, the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:8, fragments thereof, and sequences having at least 80%, more preferably at least 85%, even more preferably at least 90%, and even more preferably at least 95% or 99% sequence identity thereto, such as 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto. In another preferred embodiment, the at least one miRNA is selected from the group consisting of SEQ ID NO:1 , SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, SEQ ID NO:39, fragments thereof, and sequences having at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95% or 99%, such as 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity thereto. FIG. 9 shows preferred combinations of miRNAs having nucleotide sequences according to SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, and SEQ ID NO:39. It should be noted that when the levels of at least two miRNAs are determined, the miRNAs are referred to as a miRNA set or signature. More preferably, the miRNA set or signature is a set or signature included in Table 2. Most preferred is a combination of miRNAs having nucleotide sequences according to SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, and SEQ ID NO:39.

[0263] More specifically, the kit of the present invention comprises a means for performing next generation sequencing (NGS); at least one polynucleotide (probe) for detecting said at least one miRNA; at least one primer (e.g., a primer pair) for binding to said at least one miRNA, and / or at least one antibody capable of binding to a hybrid of said at least one polynucleotide (probe) and said at least one miRNA; Includes.

[0264] The means makes it possible to determine the level of the at least one miRNA in a blood sample of a patient suffering from cancer, and thus makes it possible to predict the response of a patient suffering from cancer to a cancer treatment, to provide a prognosis for a patient suffering from cancer, to predict side effects of a patient's cancer treatment, to monitor a patient suffering from cancer, or to decide whether to treat a patient suffering from cancer.

[0265] At least one polynucleotide (probe) may be part of a microarray / biochip or may be bound to a bead in a bead-based multiplex system. At least one polynucleotide (primer, primer pair) may be part of a RT-PCR system, a PCR-system, or a next generation sequencing system. The means may further include a microarray, a RT-PCT system, a PCR system, a flow cytometer, a Luminex system, and / or a next generation sequencing system.

[0266] Preferably, the (level of) at least one miRNA is detected / determined in a blood sample of a patient suffering from cancer. For preferred embodiments of the blood sample reference is made to the first to fourth aspects of the invention.

[0267] Even more specifically, the kits comprise means for determining the level of PD-L1 in a biological sample, such as a tissue sample, particularly from a patient suffering from cancer, which may include polynucleotides (probes), primers (e.g. primer pairs), and / or antibodies that are specific for PD-L1.

[0268] The kit of the present invention further comprises (iii) Containers; and / or (iv) Data carrier may include.

[0269] The data carrier may be a non-electronic data carrier, for example a graphical data carrier such as an information leaflet, an information sheet, a bar code, or an access code, or an electronic data carrier such as a floppy disk, a compact disk (CD), a digital versatile disk (DVD), a microchip, or another semiconductor-based electronic data carrier. The access code may enable access to a database, for example an internet database, a centralized database, or a distributed database. The access code may also enable access to application software that allows a computer to perform tasks for a computer user, or a mobile app, which is software designed to run on smartphones and other mobile devices.

[0270] The data carrier may further comprise at least one reference, such as the reference level or cut-off score of the level of the at least one miRNA determined herein. If the data carrier comprises an access code allowing access to a database, the at least one reference, such as the reference level or cut-off score, may be stored in this database. The data carrier may also comprise information or instructions on how to carry out the method according to the first to fifth aspects of the invention.

[0271] The kits may also contain materials desirable from a commercial and user standpoint, including buffers, reagents and / or diluents for determining the above-mentioned levels.

[0272] In the first to eleventh aspects, the patient suffering from cancer is preferably a mammal, particularly a human.

[0273] In all the above embodiments, combinations of miRNAs having nucleotide sequences according to SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, and SEQ ID NO:39 are most preferred.

[0274] Immunotherapy has revolutionized the standard of care for many cancers. However, a current key limitation is the lack of reliable efficacy biomarkers. For example, in advanced NSCLC expressing high levels of PD-L1 (PD-L1 tumor proportion score (TPS) ≥ 50%), immunotherapy alone or in combination with chemotherapy is recommended as a treatment option in major international guidelines. Nevertheless, there is still uncertainty regarding the ideal treatment choice in individual patients. The inventors have identified novel miRNAs that allow for the selection of patients suffering from cancer to benefit from immunochemotherapy or immunotherapy.

[0275] Thus, in a twelfth aspect, the present invention relates to an (in vitro) method for selecting a patient suffering from cancer who is (likely to) benefit from immunochemotherapy or immunotherapy, comprising determining the level of at least one miRNA (e.g. 1, 2, 3, 4 or 5 miRNAs) in a blood sample of said patient, wherein the at least one miRNA (e.g., 1, 2, 3, 4, or 5 miRNAs) is a nucleotide sequence selected from the group consisting of SEQ ID NO:1 (miR-2115-3p), SEQ ID NO:39 (miR-218-5p), SEQ ID NO:13 (miR-224-5p), SEQ ID NO:7 (miR-4676-3p), SEQ ID NO:34 (miR-6503-5p), fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, even more preferably at least 95% or 99%, such as 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto; and Here, the patient optionally has a PD-L1 Tumor Proportion Score (TPS) of ≧50%.

[0276] Patients with a PD-L1 TPS of ≥ 50% should preferably lack activating oncogenic mutations such as EGFR mutations, BRAF V660e mutations, ALK translocations, and / or ROS-1 translocations.

[0277] Further (alternatively or additionally), it is preferred that the cancer is a target of immunochemotherapy or immunotherapy. The cancer that is a target of immunochemotherapy is sensitive to immunotherapeutic agents and chemotherapeutic agents. The cancer that is a target of immunotherapy is sensitive to immunotherapeutic agents.

[0278] Specifically, the cancer to be treated with immunotherapy is sensitive to immune checkpoint inhibition. More specifically, the immune checkpoint inhibition involves the administration of at least one immune checkpoint inhibitor. Even more specifically, the at least one immune checkpoint inhibitor is an inhibitor that targets PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0279] It is also preferred (alternatively or additionally) that the cancer is selected from the group consisting of lung cancer, breast cancer, cervical cancer, gastric cancer, bladder cancer, skin cancer, nasopharyngeal cancer, neuroendocrine cancer, colon cancer, urothelial cancer, liver cancer, ovarian cancer, esophageal cancer, pancreatic cancer, kidney cancer, stomach cancer, esophageal cancer, renal cancer, head and neck cancer, brain cancer, lymphatic cancer, blood cancer, squamous cell carcinoma, laryngeal cancer, retinal cancer, prostate cancer, uterine cancer, testicular cancer, bone cancer, lymphoma, and leukemia.

[0280] More preferably, the cancer is selected from the group consisting of lung cancer, breast cancer, cervical cancer, gastric cancer, skin cancer, and bladder cancer, which cancer is a candidate for immunochemotherapy or immunotherapy. Even more preferably, the lung cancer is non-small cell lung cancer (NSCLC).

[0281] Even more preferably, the non-small cell lung cancer (NSCLC) is late stage NSCLC. Most preferably, the late stage NSCLC is stage IV NSCLC.

[0282] In one embodiment, the level of at least one miRNA is compared to a (miRisk) cut-off score, which allows to classify / select patients as patients who are (likely to) benefit from immunochemotherapy or patients who are (likely to) benefit from immunochemotherapy or immunotherapy.

[0283] Preferably, a level of at least one miRNA higher than the (miRisk) cutoff score indicates that the patient is (likely to) benefit from immunochemotherapy, or a level of at least one miRNA below the (miRisk) cutoff value indicates that the patient is (likely to) benefit from immunochemotherapy or immunotherapy.

[0284] In an alternative embodiment, the method comprises weighting at least two, at least three, at least four, or five miRNAs having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 (miR-2115-3p), SEQ ID NO:39 (miR-218-5p), SEQ ID NO:13 (miR-224-5p), SEQ ID NO:7 (miR-4676-3p), SEQ ID NO:34 (miR-6503-5p), fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, 95% or 99%, such as 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto. The method further comprises determining a (miRisk) score by summarizing the levels.

[0285] In particular, the (miRisk) score is determined by summarizing the weighted levels of five miRNAs having nucleotide sequences selected from the group consisting of SEQ ID NO:1 (miR-2115-3p), SEQ ID NO:39 (miR-218-5p), SEQ ID NO:13 (miR-224-5p), SEQ ID NO:7 (miR-4676-3p), and SEQ ID NO:34 (miR-6503-5p).

[0286] Preferably, the (miRisk) score is calculated according to the following formula: (miRisk) score = (ln(SEQ ID NO:1 (miR-2115-3p) RPM + 1) × 2.190467) + (ln(SEQ ID NO:39 (miR-218-5p) RPM + 1) × 0.303095) + (ln(SEQ ID NO:13 (miR-224-5p) RPM + 1) × 0.598415) + (ln(SEQ ID NO:7 (miR-4676-3p) RPM + 1) × 1.101122) + (ln(SEQ ID NO:34 (miR-6503-5p) RPM + 1) × 0.958823) where RPM means reads per million.

[0287] In this regard, it should be noted that the miRNA having the nucleotide sequence according to SEQ ID NO: 1 is miR-2115-3p, the miRNA having the nucleotide sequence according to SEQ ID NO: 39 is miR-218-5p, the miRNA having the nucleotide sequence according to SEQ ID NO: 13 is miR-224-5p, the miRNA having the nucleotide sequence according to SEQ ID NO: 7 is miR-4676-3p, and the miRNA having the nucleotide sequence according to SEQ ID NO: 34 is miR-6503-5p.

[0288] More preferably, the (miRisk) score as defined above is compared to a (miRisk) cut-off score.

[0289] Even more preferably, the (miRisk) cutoff score is about -0.073.

[0290] Even more preferably, A (miRisk) score > approximately -0.073 indicates that the patient is (likely) to benefit from immunochemotherapy, or a (miRisk) score ≦ approximately -0.073 indicates that the patient is (likely) to benefit from immunochemotherapy or immunotherapy.

[0291] The patient suffering from cancer is preferably a mammal, particularly a human.

[0292] For preferred embodiments of the blood sample, reference is made to the first to eleventh aspects of the invention.

[0293] In a thirteenth aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: (i) identifying a patient as one who may benefit from immunochemotherapy or immunotherapy by carrying out a method according to the twelfth aspect, and (ii) assigning the patient to the therapy; The present invention relates to an (in vitro) method for determining whether to treat a patient suffering from cancer with immunochemotherapy or immunotherapy, comprising:

[0294] As mentioned above, patients with a (miRisk) score > about -0.073 will likely benefit from immunochemotherapy and will be assigned to said treatment. Alternatively, patients with a (miRisk) score ≦ about -0.073 will likely benefit from immunochemotherapy and will be assigned to said treatment. Patients who are likely to benefit from immunotherapy are assigned to one of these treatments, in which case immunotherapy is usually chosen because it places a lower burden on the patient than immunotherapy combined with chemotherapy.

[0295] Preferably, the immunotherapeutic agent is a PD-1 / PD-L1 targeted inhibitor. More preferably, the PD-1 / PD-L1 targeted inhibitor is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, durvalumab, and atezolizumab.

[0296] Preferably, the chemotherapeutic agent is a platinum doublet.

[0297] For example, the immunotherapy agent is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, durvalumab, and atezolizumab, and / or the chemotherapy agent is a platinum doublet.

[0298] With regard to other immunotherapeutic or chemotherapeutic agents, reference is made to the first to eleventh aspects of the invention.

[0299] The patient suffering from cancer is preferably a mammal, particularly a human.

[0300] In a further aspect, the present invention provides a method for producing a method for the treatment of a cancer (i) identifying a patient as a patient who may benefit from immunochemotherapy or immunotherapy by carrying out the method according to the twelfth aspect, and (ii) treating a patient with said therapy. The present invention relates to a method for treating a patient suffering from cancer with immunochemotherapy or immunotherapy, comprising:

[0301] As mentioned above, patients with a (miRisk) score > about -0.073 will (likely) benefit from immunochemotherapy and are then treated with said therapy. Alternatively, patients with a (miRisk) score ≦ about -0.073 will (likely) benefit from immunochemotherapy or immunotherapy and are then treated with one of said therapies. In this case, immunotherapy is usually chosen because it places less of a burden on patients than immunotherapy combined with chemotherapy.

[0302] Preferably, the immunotherapeutic agent is a PD-1 / PD-L1 targeted inhibitor. More preferably, the PD-1 / PD-L1 targeted inhibitor is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, durvalumab, and atezolizumab.

[0303] Preferably, the chemotherapeutic agent is a platinum doublet.

[0304] For example, the immunotherapy agent is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, durvalumab, and atezolizumab, and / or the chemotherapy agent is a platinum doublet.

[0305] With regard to other immunotherapeutic or chemotherapeutic agents, reference is made to the first to eleventh aspects of the invention.

[0306] The patient suffering from cancer is preferably a mammal, particularly a human.

[0307] In a fourteenth aspect, the present invention relates to a kit (for use in vitro) for selecting a patient suffering from cancer who is (likely to) benefit from immunochemotherapy or immunotherapy, the kit comprising a kit for detecting in a blood sample of a patient suffering from cancer the expression of SEQ ID NO: 1 (miR-2115-3p), SEQ ID NO: 39 (miR-218-5p), SEQ ID NO: 13 ... and optionally, the patient has a PD-L1 Tumor Proportion Score (TPS) of ≧50%, wherein the patient has a PD-L1 Tumor Proportion Score (TPS) of ≧50%.

[0308] Patients with a PD-L1 TPS of ≥ 50% should preferably be free of activating oncogenic mutations such as EGFR mutations, BRAF V660e mutations, ALK translocations, and / or ROS-1 translocations.

[0309] Further (alternatively or additionally), it is preferred that the cancer is a target of immunochemotherapy or immunotherapy. The cancer that is a target of immunochemotherapy is sensitive to immunotherapeutic agents and chemotherapeutic agents. The cancer that is a target of immunotherapy is sensitive to immunotherapeutic agents.

[0310] Specifically, the cancer to be treated with immunotherapy is sensitive to immune checkpoint inhibitors. More specifically, the immune checkpoint blockade involves the administration of at least one immune checkpoint inhibitor. Even more specifically, the at least one immune checkpoint inhibitor is an inhibitor that targets PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0311] It is also preferred (alternatively or additionally) that the cancer is selected from the group consisting of lung cancer, breast cancer, cervical cancer, gastric cancer, bladder cancer, skin cancer, nasopharyngeal cancer, neuroendocrine cancer, colon cancer, urothelial cancer, liver cancer, ovarian cancer, esophageal cancer, pancreatic cancer, kidney cancer, stomach cancer, esophageal cancer, renal cancer, head and neck cancer, brain cancer, lymphatic cancer, blood cancer, squamous cell carcinoma, laryngeal cancer, retinal cancer, prostate cancer, uterine cancer, testicular cancer, bone cancer, lymphoma, and leukemia.

[0312] More preferably, the cancer is selected from the group consisting of lung cancer, breast cancer, cervical cancer, gastric cancer, skin cancer, and bladder cancer. The cancer is a target of immunochemotherapy or immunotherapy. Even more preferably, the lung cancer is non-small cell lung cancer (NSCLC).

[0313] Even more preferably, the non-small cell lung cancer (NSCLC) is late stage NSCLC. Most preferably, the late stage NSCLC is stage IV NSCLC.

[0314] As mentioned above, the kit comprises means for determining, in a blood sample of a patient suffering from cancer, at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 (miR-2115-3p), SEQ ID NO:39 (miR-218-5p), SEQ ID NO:13 (miR-224-5p), SEQ ID NO:7 (miR-4676-3p), SEQ ID NO:34 (miR-6503-5p), fragments thereof, and sequences having at least 80%, preferably at least 85%, more preferably at least 90%, even more preferably at least 95% or 99%, e.g., 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity thereto.

[0315] Specifically, the kit a means for performing next generation sequencing (NGS); at least one polynucleotide (probe) for detecting said at least one miRNA; at least one primer (e.g., a primer pair) for binding to said at least one miRNA, and / or At least one antibody capable of binding to a hybrid of said at least one polynucleotide (probe) and said at least one miRNA Includes.

[0316] Said means make it possible to determine the level of at least one miRNA in a blood sample of a patient suffering from cancer and thus to select patients suffering from cancer who are (likely to) benefit from immunochemotherapy or immunotherapy.

[0317] The at least one polynucleotide (probe) may be part of a microarray / biochip or may be bound to beads in a bead-based multiplex system. The at least one polynucleotide (primer, primer pair) may be part of a RT-PCR system, a PCR-system, or a next generation sequencing system.

[0318] The means may further comprise a microarray, a RT-PCT system, a PCR system, a flow cytometer, a Luminex system, and / or a next generation sequencing system.

[0319] As mentioned above, the (level of) at least one miRNA is detected / determined in a blood sample of a patient suffering from cancer. For preferred embodiments of the blood sample reference is made to the first to eleventh aspects of the invention.

[0320] More specifically, the kits comprise means for determining the level of PD-L1 in a biological sample (e.g., a tissue sample), particularly from a patient suffering from cancer, which may include polynucleotides (probes), primers (e.g., primer pairs), and / or antibodies that are specific for PD-L1.

[0321] More specifically, the kit is useful for carrying out the method of the twelfth aspect of the invention.

[0322] The kit may comprise instructions on how to carry out the method according to the twelfth aspect of the invention.

[0323] The kit may further comprise a container, and / or a data carrier.

[0324] The data carrier may be a non-electronic data carrier, for example a graphical data carrier such as an information leaflet, an information sheet, a bar code, or an access code, or an electronic data carrier such as a floppy disk, a compact disk (CD), a digital versatile disk (DVD), a microchip, or another semiconductor-based electronic data carrier. The access code may enable access to a database, for example an internet database, a centralized database, or a distributed database. The access code may also enable access to application software that allows a computer to perform tasks for a computer user, or a mobile app, which is software designed to run on smartphones and other mobile devices.

[0325] The data carrier may further comprise a (miRisk) cut-off score. If the data carrier comprises an access code allowing access to the database, The (miRisk) cut-off scores may be compiled into this database.

[0326] The data carrier may also contain information or instructions on how to perform the method according to the twelfth aspect of the invention.

[0327] The kits may also contain materials desirable from a commercial and user standpoint, including buffers, reagents and / or diluents for determining the above levels.

[0328] The patient suffering from cancer is preferably a mammal, particularly a human.

[0329] In a fifteenth aspect, the present invention relates to an immunotherapeutic agent for use in the treatment of cancer in a patient in combination with a chemotherapeutic agent, comprising wherein patients are defined as having a PD-L1 tumor proportion score (TPS) of ≥ 50%, and have a (miRisk) score > approximately -0.073, calculated according to the following formula: (miRisk) score = (ln(sequence number 1 (miR-2115-3p) RPM + 1) × 2.190467) + (ln(sequence number 39 (miR-218-5p) RPM + 1) × 0.303095) + (ln(sequence number 13 (miR-224-5p) RPM + 1) × 0.598415) + (ln(sequence number 7 (miR-4676-3p) RPM + 1) × 1.101122) + (ln(sequence number 34 (miR-6503-5p) RPM + 1) × 0.958823)

[0330] In this regard, it should be noted that the miRNA having the nucleotide sequence according to SEQ ID NO: 1 is miR-2115-3p, the miRNA having the nucleotide sequence according to SEQ ID NO: 39 is miR-218-5p, the miRNA having the nucleotide sequence according to SEQ ID NO: 13 is miR-224-5p, the miRNA having the nucleotide sequence according to SEQ ID NO: 7 is miR-4676-3p, and the miRNA having the nucleotide sequence according to SEQ ID NO: 34 is miR-6503-5p.

[0331] In particular, the (miRisk) score is determined in a patient's blood sample, for which preferred blood samples reference is made to the first to eleventh aspects of the invention.

[0332] Patients with a PD-L1 TPS of ≥ 50% are preferably free of activating oncogenic mutations, which may be EGFR mutations, BRAF V660e mutations, ALK translocations, and / or ROS-1 translocations.

[0333] Further (alternatively or additionally), it is preferred that the cancer is a target of immunochemotherapy or immunotherapy. The cancer that is a target of immunochemotherapy is sensitive to immunotherapeutic agents and chemotherapeutic agents. The cancer that is a target of immunotherapy is sensitive to immunotherapeutic agents. Specifically, the cancer to be treated with immunotherapy is sensitive to immune checkpoint inhibition. More specifically, the immune checkpoint inhibition involves the administration of at least one immune checkpoint inhibitor. Even more specifically, the at least one immune checkpoint inhibitor is an inhibitor that targets PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0334] The cancer is selected from the group consisting of lung cancer, breast cancer, cervical cancer, gastric cancer, bladder cancer, skin cancer, nasopharyngeal cancer, neuroendocrine cancer, colon cancer, urothelial cancer, liver cancer, ovarian cancer, esophageal cancer, pancreatic cancer, kidney cancer, stomach cancer, esophageal cancer, renal cancer, head and neck cancer, brain cancer, lymphatic cancer, blood cancer, squamous cell carcinoma, laryngeal cancer, retinal cancer, prostate cancer, uterine cancer, testicular cancer, bone cancer, lymphoma, and leukemia. Both are (alternatively or additionally) preferred.

[0335] More preferably, the cancer is selected from the group consisting of lung cancer, breast cancer, cervical cancer, gastric cancer, skin cancer and bladder cancer.The cancer is the subject of immunochemotherapy or immunotherapy.Even more preferably, the lung cancer is non-small cell lung cancer (NSCLC).

[0336] Even more preferably, the non-small cell lung cancer (NSCLC) is late stage NSCLC, and most preferably, the late stage NSCLC is stage IV NSCLC.

[0337] Specifically, the immunotherapeutic agent is an inhibitor that targets PD-1 / PD-L1. More specifically, the inhibitor that targets PD-1 / PD-L1 is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, durvalumab, and atezolizumab.

[0338] Specifically, the chemotherapeutic agent used in combination is a platinum doublet.

[0339] For example, the immunotherapy agent is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, durvalumab, and atezolizumab, and the chemotherapy agent is a platinum doublet.

[0340] Regarding other immunotherapeutic or chemotherapeutic agents, reference is made to the first to eleventh aspects of the invention.

[0341] The components of the combination, ie, the immunotherapeutic agent and the chemotherapeutic agent, may be administered together or independently of each other (eg, one after the other).

[0342] The patient suffering from cancer is preferably a mammal, particularly a human.

[0343] This aspect of the invention can also be expressed as follows: In a fifteenth aspect, the present invention relates to the use of an immunotherapeutic agent in combination with a chemotherapeutic agent for the manufacture of a medicament for the treatment of cancer, comprising Here, patients have a PD-L1 tumor proportion score (TPS) of ≧50% and a (miRisk) score > approximately −0.073 calculated according to the following formula: (miRisk) score = (ln(sequence number 1 (miR-2115-3p) RPM + 1) × 2.190467) + (ln(sequence number 39 (miR-218-5p) RPM + 1) × 0.303095) + (ln(sequence number 13 (miR-224-5p) RPM + 1) × 0.598415) + (ln(sequence number 7 (miR-4676-3p) RPM + 1) × 1.101122) + (ln(sequence number 34 (miR-6503-5p) RPM + 1) × 0.958823)

[0344] Alternatively, in a fifteenth aspect, the present invention provides a method for producing a composition comprising the steps of: (i) determining in the patient blood sample a (miRisk) score > about -0.073 calculated according to the following formula: (miRisk) score = (ln(sequence number 1 (miR-2115-3p) RPM + 1) × 2.190467) + (ln(sequence number 39 (miR-218-5p) RPM + 1) × 0.303095) + (ln(sequence number 13 (miR-224-5p) RPM + 1) × 0.598415) + (ln(sequence number 7 (miR-4676-3p) RPM + 1) × 1.101122) + (ln(sequence number 34 (miR-6503-5p) RPM + 1) × 0.958823), and (ii) administering to a patient in need thereof (an effective amount of an immunotherapeutic agent) in combination with a chemotherapeutic agent; Administering and a method for treating cancer in a patient, comprising: Here, the patient has a PD-L1 Tumor Proportion Score (TPS) of ≧50%.

[0345] In a sixteenth aspect, the present invention relates to a chemotherapeutic agent for use in the treatment of cancer in a patient in combination with an immunotherapeutic agent, comprising Here, the patient PD-L1 Tumor Proportion Score (TPS) of ≥ 50%, and have a (miRisk) score > approximately -0.073, calculated according to the following formula: (miRisk) score = (ln(sequence number 1 (miR-2115-3p) RPM + 1) × 2.190467) + (ln(sequence number 39 (miR-218-5p) RPM + 1) × 0.303095) + (ln(sequence number 13 (miR-224-5p) RPM + 1) × 0.598415) + (ln(sequence number 7 (miR-4676-3p) RPM + 1) × 1.101122) + (ln(sequence number 34 (miR-6503-5p) RPM + 1) × 0.958823)

[0346] In this regard, it should be noted that the miRNA having the nucleotide sequence according to SEQ ID NO: 1 is miR-2115-3p, the miRNA having the nucleotide sequence according to SEQ ID NO: 39 is miR-218-5p, the miRNA having the nucleotide sequence according to SEQ ID NO: 13 is miR-224-5p, the miRNA having the nucleotide sequence according to SEQ ID NO: 7 is miR-4676-3p, and the miRNA having the nucleotide sequence according to SEQ ID NO: 34 is miR-6503-5p.

[0347] In particular, the (miRisk) score is determined in a patient's blood sample, for which preferred blood samples reference is made to the first to eleventh aspects of the invention.

[0348] Patients with a PD-L1 TPS of ≥ 50% should preferably be free of activating oncogenic mutations such as EGFR mutations, BRAF V660e mutations, ALK translocations, and / or ROS-1 translocations.

[0349] Further (alternatively or additionally), it is preferred that the cancer is a target of immunochemotherapy or immunotherapy. The cancer that is a target of immunochemotherapy is sensitive to immunotherapeutic agents and chemotherapeutic agents. The cancer that is a target of immunotherapy is sensitive to immunotherapeutic agents.

[0350] Specifically, the cancer to be treated with immunotherapy is sensitive to immune checkpoint inhibition. More specifically, the immune checkpoint inhibition involves the administration of at least one immune checkpoint inhibitor. Even more specifically, the at least one immune checkpoint inhibitor is an inhibitor that targets PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0351] It is also preferred (alternatively or additionally) that the cancer is selected from the group consisting of lung cancer, breast cancer, cervical cancer, gastric cancer, bladder cancer, skin cancer, nasopharyngeal cancer, neuroendocrine cancer, colon cancer, urothelial cancer, liver cancer, ovarian cancer, esophageal cancer, pancreatic cancer, kidney cancer, stomach cancer, esophageal cancer, renal cancer, head and neck cancer, brain cancer, lymphatic cancer, blood cancer, squamous cell carcinoma, laryngeal cancer, retinal cancer, prostate cancer, uterine cancer, testicular cancer, bone cancer, lymphoma, and leukemia.

[0352] More preferably, the cancer is selected from the group consisting of lung cancer, breast cancer, cervical cancer, gastric cancer, skin cancer, and bladder cancer, which cancer is a candidate for immunochemotherapy or immunotherapy. Even more preferably, the lung cancer is non-small cell lung cancer (NSCLC).

[0353] Even more preferably, the non-small cell lung cancer (NSCLC) is late stage NSCLC, and most preferably, the late stage NSCLC is stage IV NSCLC.

[0354] Specifically, the chemotherapeutic agent is a platinum doublet.

[0355] Specifically, the immunotherapeutic agent used in combination is an inhibitor targeting PD-1 / PD-L1. More specifically, the inhibitor targeting PD-1 / PD-L1 is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, durvalumab, and atezolizumab.

[0356] For example, the chemotherapy agent is a platinum doublet and the immunotherapy agent is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, durvalumab, and atezolizumab.

[0357] Regarding other chemotherapeutic or immunotherapeutic agents, reference is made to the first to eleventh aspects of the invention.

[0358] The components of the combination, ie, the chemotherapeutic agent and the immunotherapeutic agent, may be administered together or independently of each other (eg, one after the other).

[0359] The patient suffering from cancer is preferably a mammal, particularly a human.

[0360] This aspect of the invention can also be expressed as follows: In a sixteenth aspect, the present invention relates to the use of a chemotherapeutic agent in combination with an immunotherapeutic agent for the manufacture of a medicament for the treatment of cancer, Here, the patient has a PD-L1 Tumor Proportion Score (TPS) of ≧50% and a (miRisk) score > approximately −0.073, calculated according to the following formula: (miRisk) score = (ln(sequence number 1 (miR-2115-3p) RPM + 1) × 2.190467) + (ln(sequence number 39 (miR-218-5p) RPM + 1) × 0.303095) + (ln(sequence number 13 (miR-224-5p) RPM + 1) × 0.598415) + (ln(sequence number 7 (miR-4676-3p) RPM + 1) × 1.101122) + (ln(sequence number 34 (miR-6503-5p) RPM + 1) × 0.958823)

[0361] Alternatively, in a sixteenth aspect, the present invention provides a method for producing a composition comprising the steps of: (i) determining in the patient blood sample a (miRisk) score > about -0.073 calculated according to the following formula: (miRisk) score = (ln(SEQ ID NO: 1 (miR-2115-3p) RPM + 1) × 2.190467) + (ln(SEQ ID NO: 39 (miR-218-5p) RPM + 1) × 0.303095) + (ln(SEQ ID NO: 13 (miR-224-5p) RPM + 1) × 0.598415) + (ln(SEQ ID NO: 7 (miR-4676-3p) RPM + 1) × 1.101122) + (ln(SEQ ID NO: 34 (miR-6503-5p) RPM + 1) × 0.958823), and (ii) administering (an effective amount of) a chemotherapeutic agent in combination with an immunotherapeutic agent to a patient in need thereof. and a method for treating cancer in a patient, comprising: Here, patients have a PD-L1 Tumor Proportion Score (TPS) of ≧50%.

[0362] In a seventeenth aspect, the present invention relates to an immunotherapeutic agent for use in the treatment of cancer in a patient, optionally in combination with a chemotherapeutic agent, comprising: Here, the patient PD-L1 tumor proportion score ≥ 50%, and have a (miRisk) score of ≦about −0.073 calculated according to the following formula: (miRisk) score = (ln(sequence number 1 (miR-2115-3p) RPM + 1) × 2.190467) + (ln(sequence number 39 (miR-218-5p) RPM + 1) × 0.303095) + (ln(sequence number 13 (miR-224-5p) RPM + 1) × 0.598415) + (ln(sequence number 7 (miR-4676-3p) RPM + 1) × 1.101122) + (ln(sequence number 34 (miR-6503-5p) RPM + 1) × 0.958823)

[0363] In this regard, it should be noted that the miRNA having the nucleotide sequence according to SEQ ID NO: 1 is miR-2115-3p, the miRNA having the nucleotide sequence according to SEQ ID NO: 39 is miR-218-5p, the miRNA having the nucleotide sequence according to SEQ ID NO: 13 is miR-224-5p, the miRNA having the nucleotide sequence according to SEQ ID NO: 7 is miR-4676-3p, and the miRNA having the nucleotide sequence according to SEQ ID NO: 34 is miR-6503-5p.

[0364] In particular, the (miRisk) score is determined in a patient's blood sample, for which preferred blood samples reference is made to the first to eleventh aspects of the invention.

[0365] In patients with PD-L1 TPS ≥ 50%, it is desirable to have no activating oncogenic mutations, which may be EGFR mutations, BRAF V660e mutations, ALK translocations, and / or ROS-1 translocations.

[0366] Further (alternatively or additionally), it is preferred that the cancer is a target of immunochemotherapy or immunotherapy. The cancer that is a target of immunochemotherapy is sensitive to immunotherapeutic agents and chemotherapeutic agents. The cancer that is a target of immunotherapy is sensitive to immunotherapeutic agents.

[0367] Specifically, the cancer to be treated with immunotherapy is sensitive to immune checkpoint inhibition. More specifically, the immune checkpoint inhibition involves the administration of at least one immune checkpoint inhibitor. Even more specifically, the at least one immune checkpoint inhibitor is an inhibitor that targets PD-1 / PD-L1 or the PD-1 / PD-L1 pathway.

[0368] It is also preferred (alternatively or additionally) that the cancer is selected from the group consisting of lung cancer, breast cancer, cervical cancer, gastric cancer, bladder cancer, skin cancer, nasopharyngeal cancer, neuroendocrine cancer, colon cancer, urothelial cancer, liver cancer, ovarian cancer, esophageal cancer, pancreatic cancer, kidney cancer, stomach cancer, esophageal cancer, renal cancer, head and neck cancer, brain cancer, lymphatic cancer, blood cancer, squamous cell carcinoma, laryngeal cancer, retinal cancer, prostate cancer, uterine cancer, testicular cancer, bone cancer, lymphoma, and leukemia.

[0369] More preferably, the cancer is selected from the group consisting of lung cancer, breast cancer, cervical cancer, gastric cancer, skin cancer, and bladder cancer. The cancer is a target of immunochemotherapy or immunotherapy. Even more preferably, the lung cancer is non-small cell lung cancer (NSCLC).

[0370] Even more preferably, the non-small cell lung cancer (NSCLC) is late stage NSCLC. Most preferably, the late stage NSCLC is stage IV NSCLC.

[0371] Specifically, the immunotherapeutic agent is an inhibitor that targets PD-1 / PD-L1. More specifically, the inhibitor that targets PD-1 / PD-L1 is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, durvalumab, and atezolizumab.

[0372] Specifically, the chemotherapeutic agent optionally used in combination with the immunotherapeutic agent is a platinum doublet.

[0373] For example, the immunotherapy agent is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, durvalumab, and atezolizumab, and the chemotherapy agent is a platinum doublet.

[0374] Regarding other immunotherapeutic or chemotherapeutic agents, reference is made to the first to eleventh aspects of the invention.

[0375] The components of the combination, ie, immunotherapeutic agent and chemotherapeutic agent, when present, can be administered together or independently of each other (eg, one after the other).

[0376] The patient suffering from cancer is preferably a mammal, particularly a human.

[0377] This aspect of the invention can also be expressed as follows: In a seventeenth aspect, the present invention relates to the use of an immunotherapeutic agent, optionally in combination with a chemo-immunotherapeutic agent, for the manufacture of a medicament for the treatment of cancer in a patient, Here, the patient is PD-L1 Tumor Proportion Score (TPS) >50%, and have a (miRisk) score of ≦about −0.073, calculated according to the following formula: (miRisk) score = (ln(sequence number 1 (miR-2115-3p) RPM + 1) × 2.190467) + (ln(sequence number 39 (miR-218-5p) RPM + 1) × 0.303095) + (ln(sequence number 13 (miR-224-5p) RPM + 1) × 0.598415) + (ln(sequence number 7 (miR-4676-3p) RPM + 1) × 1.101122) + (ln(sequence number 34 (miR-6503-5p) RPM + 1) × 0.958823)

[0378] Alternatively, in a seventeenth aspect, the present invention provides a method for producing a composition comprising the steps of: (i) determining in the patient blood sample a (miRisk) score of ≦about −0.073 calculated according to the following formula: (miRisk) score = (ln(SEQ ID NO:1 (miR-2115-3p) RPM + 1) x 2.190467) + (ln(SEQ ID NO:39 (miR-218-5p) RPM + 1) x 0.303095) + (ln(SEQ ID NO:13 (miR-224-5p) RPM + 1) x 0.598415) + (ln(SEQ ID NO:7 (miR-4676-3p) RPM + 1) x 1.101122) + (ln(SEQ ID NO:34 (miR-6503-5p) RPM + 1) x 0.958823), and (ii) administering to a patient in need thereof an (effective amount of) an immunotherapeutic agent, optionally in combination with a chemotherapeutic agent; and a method for treating cancer in a patient, comprising: Here, the patients have a PD-L1 Tumor Proportion Score (TPS) of ≧50%.

[0379] The cancer in the twelfth to seventeenth aspects of the present invention is most preferably lung cancer.

[0380] In this respect, the present invention provides 1. A method for selecting a patient suffering from lung cancer to benefit from immunochemotherapy or immunotherapy, comprising determining the level of at least one miRNA in a blood sample of said patient, wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO:1 (miR-2115-3p), SEQ ID NO:39 (miR-218-5p), SEQ ID NO:13 (miR-224-5p), SEQ ID NO:7 (miR-4676-3p), SEQ ID NO:34 (miR-6503-5p), fragments thereof, and sequences having at least 80% sequence identity thereto; and wherein the patient has a PD-L1 Tumor Proportion Score (TPS) of ≥ 50%; It concerns the method.

[0381] 2. The method of item 1, wherein the patients with ≥ 50% PD-L1 TPS do not have activating oncogene mutations.

[0382] 3. The method of item 1 or 2, wherein the lung cancer is non-small cell lung cancer (NSCLC).

[0383] 4. The method of item 3, wherein the non-small cell lung cancer (NSCLC) is late-stage NSCLC.

[0384] 5. The method of item 4, wherein the late stage NSCLC is stage IV NSCLC.

[0385] 6. The method of any one of items 1 to 5, wherein the level of the at least one miRNA is compared to a (miRisk) cut-off score.

[0386] 7. The method of item 6, wherein a level of the at least one miRNA higher than the (miRisk) cutoff score indicates that the patient will benefit from immunochemotherapy, or a level of the at least one miRNA below the (miRisk) cutoff score indicates that the patient will benefit from immunochemotherapy or immunotherapy.

[0387] 8. The method of any one of items 1 to 7, further comprising a step of determining a (miRisk) score by aggregating the weighted levels of at least two, at least three, at least four, or five miRNAs having a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 (miR-2115-3p), SEQ ID NO: 39 (miR-218-5p), SEQ ID NO: 13 (miR-224-5p), SEQ ID NO: 7 (miR-4676-3p), SEQ ID NO: 34 (miR-6503-5p), fragments thereof, and sequences having at least 80% sequence identity thereto.

[0388] 9. The method of item 8, wherein the (miRisk) score is determined by aggregating the weighted levels of five miRNAs having nucleotide sequences selected from the group consisting of SEQ ID NO:1 (miR-2115-3p), SEQ ID NO:39 (miR-218-5p), SEQ ID NO:13 (miR-224-5p), SEQ ID NO:7 (miR-4676-3p), and SEQ ID NO:34 (miR-6503-5p).

[0389] 10. The method of item 8 or 9, wherein the (miRisk) score is calculated according to the following formula: (miRisk) score = (ln(sequence number 1 (miR-2115-3p) RPM + 1) × 2.190467) + (ln(sequence number 39 (miR-218-5p) RPM + 1) × 0.303095) + (ln(sequence number 13 (miR-224-5p) RPM + 1) × 0.598415) + (ln(sequence number 7 (miR-4676-3p) RPM + 1) × 1.101122) + (ln(sequence number 34 (miR-6503-5p) RPM + 1) × 0.958823) where RPM means reads per million.

[0390] 11. The method of any one of items 8 to 10, wherein the (miRisk) score is compared to a (miRisk) cut-off score.

[0391] 12. (miRisk) A method according to item 11, in which the cut-off score is approximately -0.073.

[0392] 13. (miRisk) score > approx. -0.073 indicates that the patient will benefit from immunochemotherapy, or 13. The method of item 12, wherein a (miRisk) score of ≦about −0.073 indicates that immunochemotherapy or immunotherapy would be beneficial.

[0393] 14. (i) identifying the patient as one who would benefit from immunochemotherapy or immunotherapy by carrying out any of the methods described in items 1 to 13; and (ii) assigning the patient to the therapy; 23. A method for determining whether to treat a patient suffering from lung cancer with immunochemotherapy or immunotherapy, comprising:

[0394] 15. (i) identifying the patient as one who would benefit from immunochemotherapy or immunotherapy by carrying out any of the methods described in items 1 to 13; (ii) treating the patient with the therapy. 23. A method for treating a patient suffering from lung cancer with immunochemotherapy or immunotherapy comprising:

[0395] 16. A kit for selecting a patient suffering from lung cancer to benefit from immunochemotherapy or immunotherapy, the kit comprising: The method includes determining the level of at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 (miR-2115-3p), SEQ ID NO:39 (miR-218-5p), SEQ ID NO:13 (miR-224-5p), SEQ ID NO:7 (miR-4676-3p), SEQ ID NO:34 (miR-6503-5p), fragments thereof, and sequences having at least 80% sequence identity thereto, in a blood sample of a patient suffering from lung cancer, wherein the patient has a PD-L1 Tumor Proportion Score (TPS) of ≧50%.

[0396] 17. The kit of item 16, in which patients with PD-L1 TPS of ≥ 50% do not have oncogene activating mutations.

[0397] 18. The kit of item 16 or 17, wherein the lung cancer is non-small cell lung cancer (NSCLC).

[0398] 19. The kit of item 18, wherein the non-small cell lung cancer (NSCLC) is late-stage NSCLC.

[0399] 20. The kit of item 19, wherein the late stage NSCLC is stage IV NSCLC.

[0400] 21. The kit according to any one of items 16 to 20, further comprising instructions on how to carry out the method of any one of items 1 to 13.

[0401] 22. The kit according to any one of items 16 to 21, wherein the kit is useful for carrying out the method according to any one of items 1 to 13.

[0402] 23. An immunotherapeutic agent for use in treating lung cancer in a patient in combination with a chemotherapeutic agent, comprising: wherein the patient PD-L1 Tumor Proportion Score (TPS) of ≥ 50%, and have a (miRisk) score > approximately -0.073, calculated according to the following formula: (miRisk) score = (ln(SEQ ID NO: 1 (miR-2115-3p) RPM + 1) × 2.190467) + (ln(SEQ ID NO: 39 (miR-218-5p) RPM + 1) × 0.303095) + (ln(SEQ ID NO: 13 (miR-224-5p) RPM + 1) × 0.598415) + (ln(SEQ ID NO: 7 (miR-4676-3p) RPM + 1) × 1.101122) + (ln(SEQ ID NO: 34 (miR-6503-5p) RPM + 1) × 0.958823)

[0403] 24. The immunotherapy agent for use according to item 23, wherein the patient with PD-L1 TPS of ≧50% does not have an activating oncogene mutation.

[0404] 25. The immunotherapy agent for use in accordance with item 23 or 24, wherein the lung cancer is non-small cell lung cancer (NSCLC).

[0405] 26. The immunotherapy agent for use in accordance with item 25, wherein the non-small cell lung cancer (NSCLC) is late-stage NSCLC.

[0406] 27. The immunotherapy drug for use in accordance with item 26, wherein the late stage NSCLC is stage IV NSCLC.

[0407] 28. An immunotherapeutic agent for use in any one of items 23 to 27, wherein the immunotherapeutic agent is an inhibitor targeting PD-1 / PD-L1.

[0408] 29. The immunotherapy agent for use according to item 28, wherein the inhibitor targeting PD-1 / PD-L1 is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, durvalumab, and atezolizumab.

[0409] 30. A chemotherapeutic agent for use in treating lung cancer in a patient in combination with an immunotherapeutic agent, comprising: wherein the patient has a PD-L1 tumor proportion score (TPS) of ≧50% and a (miRisk) score > approximately −0.073, calculated according to the following formula: (miRisk) score = (ln(sequence number 1 (miR-2115-3p) RPM + 1) × 2.190467) + (ln(sequence number 39 (miR-218-5p) RPM + 1) × 0.303095) + (ln(sequence number 13 (miR-224-5p) RPM + 1) × 0.598415) + (ln(sequence number 7 (miR-4676-3p) RPM + 1) × 1.101122) + (ln(sequence number 34 (miR-6503-5p) RPM + 1) × 0.958823)

[0410] 31. A chemotherapy agent for use according to item 30, wherein the patient with PD-L1 TPS of ≧50% does not have a mutation that activates an oncogene.

[0411] 32. The chemotherapeutic agent for use in accordance with item 30 or 31, wherein the lung cancer is non-small cell lung cancer (NSCLC).

[0412] 33. The chemotherapeutic agent for use in accordance with item 32, wherein the non-small cell lung cancer (NSCLC) is late-stage NSCLC.

[0413] 34. The method for use of item 33, wherein the late stage NSCLC is stage IV NSCLC. Therapeutic agents.

[0414] 35. A chemotherapeutic agent for use according to any one of items 30 to 34, wherein the chemotherapeutic agent is a platinum doublet.

[0415] 36. An immunotherapeutic agent for use in treating lung cancer in a patient, optionally in combination with a chemotherapeutic agent. wherein the patient has a PD-L1 Tumor Proportion Score (TPS) of ≧50% and a (miRisk) score ≦about −0.073, calculated according to the following formula: (miRisk) score = (ln(sequence number 1 (miR-2115-3p) RPM + 1) × 2.190467) + (ln(sequence number 39 (miR-218-5p) RPM + 1) × 0.303095) + (ln(sequence number 13 (miR-224-5p) RPM + 1) × 0.598415) + (ln(sequence number 7 (miR-4676-3p) RPM + 1) × 1.101122) + (ln(sequence number 34 (miR-6503-5p) RPM + 1) × 0.958823)

[0416] 37. The immunotherapy agent for use according to item 36, wherein the patient with PD-L1 TPS of ≧50% does not have an activating oncogene mutation.

[0417] 38. The immunotherapy agent for use in accordance with item 36 or 37, wherein the lung cancer is non-small cell lung cancer (NSCLC).

[0418] 39. The immunotherapy agent for use in accordance with item 38, wherein the non-small cell lung cancer (NSCLC) is late-stage NSCLC.

[0419] 40. The immunotherapy drug for use in accordance with item 39, wherein the late stage NSCLC is stage IV NSCLC.

[0420] 41. The immunotherapeutic agent for use according to any one of items 36 to 40, wherein the immunotherapeutic agent is an inhibitor targeting PD-1 / PD-L1.

[0421] 42. The immunotherapy agent for use according to item 41, wherein the inhibitor targeting PD-1 / PD-L1 is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, durvalumab, and atezolizumab.

[0422] 43. The immunotherapy agent for use according to any one of items 36 to 42, wherein the desired chemotherapeutic agent is a platinum doublet.

[0423] Various modifications and variations of the present invention will be apparent to those skilled in the art without departing from the scope of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the relevant fields are intended to be covered by the present invention. [Brief description of the drawings]

[0424] The following drawings are merely illustrative of the invention and should not be construed as in any way limiting the scope of the invention as set forth by the appended claims. [Figure 1]Figure 1: (A) An unbiased pipeline for univariate model selection. 1) Data are split 50:50 into train and test sets. 2) A univariate Cox proportional hazards model is fitted to each feature in the test set. 3) The single best model is used to predict the unseen test data. 4) The predictions are fit to a Cox proportional hazards model, whose significance is a marker of the accuracy of the prediction. This process can be repeated iteratively with a random 50:50 split to generate a distribution of model performance. (B) Distribution of model performance with the univariate pipeline applied to accurately annotated survival data. All models to the left of the red vertical line make statistically significant predictions on the test data. (C) Four iterations of the pipeline on data with randomized survival information. Very few significant predictive models are produced. [Diagram 2] Figure 2: (A) An unbiased pipeline for multivariate model selection. 1) Data are split 50:50 into train and test sets. 2) A multivariate Cox proportional hazards model is fitted to each feature in the test set and all models with significance less than 0.001 are selected to create a multivariate model. 3) The multivariate model is used to predict unseen test data. 4) The predictions are fitted to a Cox proportional hazards model, whose significance is a marker of the accuracy of the prediction. This process can be repeated iteratively with a random 50:50 split to generate a distribution of model performance. (B) Distribution of model performance with the multivariate pipeline applied to accurately annotated survival data. All models to the left of the red vertical line make statistically significant predictions on the test data. A summary of the best models is shown in Table 2. (C) The best models (miR-2115-3p and miR-25-3p) were fitted to a representative 50% split test data and used to classify patients into high or low risk by a median risk score cutoff value. (D) The previously fitted model was used to predict unseen test data and classify them into high and low risk using the previously defined risk threshold, with the low risk group having significantly longer survival (log-rank test, p-value 0.011). [Diagram 3]Figure 3: (A) miR-2115-3p displays a striking cell type-specific expression pattern, with expression restricted to cells of myeloid lineage. (B) PD-L1 (CD274) contains a strong predicted miR-2115-3p target site within its 3'UTR. (C) miR-2115-3p is downregulated in responders compared to non-responders. [Figure 4] Figure 4: Overall survival (OS) of NSCLC patients stratified by miRisk score. ac Comparison of overall survival between low and high miRisk score groups in the training cohort (n=96), validation immunotherapy cohort (n=84), and validation immunochemotherapy cohort (n=139). Significant differences in OS were observed in the training and validation immunotherapy cohorts, but not in the validation chemoimmunotherapy cohort. de Comparison of overall survival between patients stratified by PD-L1 TPS in the training cohort (n=96), validation immunotherapy cohort (n=84), and validation immunochemotherapy cohort (n=139). The difference in overall survival did not reach significance in any cohort. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using univariate Cox regression analysis, and P values ​​were calculated using the log-rank test. All statistical analyses were two-sided. [Diagram 5] Fig. 5: Overall survival (OS) of low-risk and high-risk patients stratified by the random forest model. ab Comparison of OS between low-risk and high-risk patients in the training cohort (n=96) and validation immunotherapy cohort (n=84). [Figure 6]Figure 6: Expression of miRisk miRNAs in low and high risk patients. ae Relative expression levels of five miRisk miRNAs between low and high risk patients measured by small RNA sequencing. fj Relative expression levels of five miRisk miRNAs between low and high risk patients measured by qRT-PCR. Mean expression of triplicate measurements is shown. qRT-PCR expression was normalized according to the ΔCt method (CtmiRNA of interest-Ctmean of HK miRNAs). All statistical tests were two-tailed unpaired t-tests. Error bars indicate standard deviation. RPM=reads per million. *=P value<0.05, **=P value<0.005, ***=P value<0.0005, ****=P value<0.00005, ns=not significant. [Figure 7] Figure 7: Overall survival of low and high miRisk patients in the external validation control cohort. 19 treatment-naïve stage IV NSCLC patients recruited in Grosshansdorf, Germany were stratified by low / high miRisk score. No significant difference in OS survival curves is observed. [Figure 8] Figure 8: Overall survival of low- and high-risk patients stratified by multivariate Cox proportional hazards model incorporating PD-L1 TPS and miRisk miRNAs. ac Comparison of overall survival between low / high groups in the training cohort (n=96), validation immunotherapy cohort (n=84), and validation immunochemotherapy cohort (n=139). Similar to the miRisk model, significant differences in overall survival were observed in the training and validation immunotherapy cohorts, but not in the validation chemoimmunotherapy cohort. The magnitude of the hazard ratios is smaller than that observed in the miRisk model. [Figure 9] Figure 9: Preferred miRNAs and miRNA combinations are shown. Preferred miRNAs have a nucleotide sequence according to SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 34, or SEQ ID NO: 39. In all embodiments described herein, miRNA combinations having a nucleotide sequence according to SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 34, and SEQ ID NO: 39 are most preferred. [Figure 10] Figure 10: Overall survival of NSCLC patients stratified by miRisk. ab Comparison of overall survival between low and high miRisk score groups in the independent validation of PD-1 / PD-L1 inhibitor monotherapy (n=56) and chemoimmunotherapy control cohorts (n=31). A significant difference in OS was observed in the independent validation cohort but not in the control cohort. cd Comparison of overall survival between immunomonotherapy (IO) and immunochemotherapy (ICT) in miRisk stratified cohorts. Hazard ratios (HRs) and 95% confidence intervals were calculated using univariate Cox regression analysis, and P values ​​were calculated using the log-rank test. All statistical analyses were two-sided. EXAMPLES

[0425] The following examples are for illustrative purposes only and are not intended to limit the above invention in any way.

[0426] 1. Example 1 97PAX gene samples were collected from untreated stage IV lung cancer patients before starting immunotherapy (pembrolizumab or nivolumab), and corresponding clinical data, including response and survival information, were also collected. Small RNAs were extracted and sequenced to measure miRNA expression profiles, which were then used to develop predictive signatures.

[0427] To identify miRNAs that may be able to predict survival, an initial exploratory analysis was performed on the miRNA expression data. Univariate Cox proportional hazards models were fitted to each feature in turn to generate a shortlist of miRNAs that were significantly associated with survival time (p-value < 0.05). This analysis resulted in 44 miRNAs that predicted survival and predicted response to immunotherapy (Table 1).

[0428] [Table 1]

[0429] Next, an unbiased pipeline was constructed (Figure 1A). It first splits the data into 50:50 training and test datasets. A univariate survival model (Cox proportional hazards model) is fitted sequentially to each miRNA in the training set. The best performing model is selected to predict the unseen training dataset. The predictions on the training dataset are used as input to fit additional survival models. Prediction performance is judged based on the significance with which the predictions can be fitted to the test dataset. This process is repeated 250 times to measure the distribution of model performance across a series of random test / train splits (Figure 1B). The pipeline was applied to the miRNA expression data and the randomized survival data to perform a random permutation control (Figure 1C). In 54% of the iterations on the true dataset, the pipeline selects miR-2115-3p (SEQ ID NO: 1) as the most predictive feature (the most frequently selected feature in the randomized dataset is selected in only 8% of the iterations). Taken together, this is evidence that miR-2115-3p is associated with survival after immunotherapy treatment and that the strength of the association exceeds that observed in models fitted to noise in the randomized dataset. The other 43 miRNAs that were predictors of survival and response to immunotherapy are shown in Table 1.

[0430] Finally, a second pipeline (Figure 2A) was constructed. The data was split 50:50 into training and testing datasets. Feature selection was performed with the testing dataset by selecting all features for which a significant univariate Cox model could be fitted (p-value < threshold). The selected features were then used to fit a multivariate Cox model to the training data and predict the testing data. The predictions were fitted to univariate Cox models, where significance is the measure of predictive performance. This process was run 3500 times to identify optimal features and evaluate the models (Figure 2B and Table 2). The preferred miRNAs and miRNA combinations (sets / signatures) are listed in Table 2.

[0431] [Table 2]

[0432] This optimized model (composed of miR-2115-3p and miR-25-3p) was used to predict the responder / non-responder status of patients in the training and testing datasets (based on a threshold risk score defined as the median risk in the training dataset). In both the training and testing datasets (a single representative 50:50 split), it was possible to predict a cohort of responding patients with significantly increased survival (Figure 2D). miR-2115-3p was confirmed to be downregulated in responders compared to non-responders (Figure 3C).

[0433] miR-2115-3p stood out as the most predictive signature and was found to have specific expression in relevant cell populations in the blood (monocytes and neutrophils, Figure 3A). Furthermore, a miR-2115-3p target site exists within the 3'UTR of PD-L1 (Figure 3B).

[0434] Summary: Novel miRNAs associated with response to immune checkpoint inhibitors of the PD-1 / PD-L1 inhibitor class have been identified in patients with previously untreated stage IV NSCLC. Furthermore, miRNAs predictive of response to PD-1 / PD-L1 inhibitors in stage IV NSCLC were identified. iRNA-based signatures have been identified, and the miRNA / miRNA-based signatures described above also enable survival prediction.

[0435] Table 3 lists the identified miRNAs with their SEQ ID NOs and nucleotide sequences:

[0436] [Table 3]

[0437] 2. Example 2 2.1 Method Patient Enrollment The test was approved by the ethical committees of the University of Heidelberg (S-296 / 2016, S-089 / 2019) and the Grosshansdorf Hospital (AZ 12-238). All patients with advanced NSCLC treated with immunotherapy alone or immunotherapy plus chemotherapy at the Thoraxklinik Heidelberg from whom blood samples were available were included. These were collected prospectively as published (Wessels et al., 2020) and provided by the Lungenbiobank Heidelberg for the present analysis in accordance with the relevant regulations. All eligible patients who received immunotherapy alone were enrolled in a training cohort. Eligible patients were included in the immunotherapy or immunochemotherapy validation cohorts, depending on the respective treatment. The diagnosis of NSCLC was performed on tissue specimens according to the criteria of the current WHO classification of lung cancer (2015) at the Institute of Pathology Heidelberg. Clinical data and laboratory results were collected by systematic review of patient records. The following clinical data were extracted: ECOG performance status (PS), smoking status, PD-L1 tumor proportion score (TPS), laboratory results, systemic and local anticancer treatment, demographic, baseline clinical and tumor characteristics including date of progression, date of last follow-up, and date of death. Neutrophil-to-lymphocyte ratio (NLR) was dichotomized at the literature cutoff value of 5, which corresponds to the median value in untreated patients (Suh, KJ et al. (2018) Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.Cancer Immunol Immunother 67, 459-470;Valero,C.et al.(2021) Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun 12, 729). PD-L1 TPS was assessed using clone SP263 (Ventana / Roche, Mannheim, Germany) and trichotomized for analysis as <1%, 1-49%, and ≥50%, reflecting the relevant clinical thresholds in current treatment guidelines (Hanna,NH et al.(2020) Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations:ASCO and OH(CCO)Joint Guideline Update.J Clin Oncol 38,1608-1632). In addition, a small cohort of patients newly diagnosed with metastatic NSCLC and choosing best supportive care was recruited as non-immunotherapy controls from Lungenclinic Grosshansdorf after approval by the local ethical committee (AZ 12-238).

[0438] PAXgene collection and processing PAXgene (PreAnalytiX, Hombrechtikon, Switzerland) blood samples were collected according to the manufacturer's instructions, immediately inverted 10 times, and frozen at -20 °C within 2 h. For long-term storage, tubes were transferred to -80 °C. Training cohort: PAXgene tubes were thawed overnight and extracted using the PAXgene Blood miRNA Kit (Qiagen, Venlo, Netherlands) according to the manufacturer's instructions. 80 μL of eluate in RNase-free water was stored at -80 °C. Validation cohort: PAXgene tubes were thawed overnight and RNA was extracted using the PAXgene Blood RNA Kit (Qiagen, Venlo, Netherlands). The flow-through was saved and stored at -20°C and used for further extraction of RNA <200 nts in length. For this purpose, the alcohol content of the samples was brought to 50% (w / v) with isopropanol and the samples were further processed using the PAXgene Blood miRNA Kit, starting from the RNA column step. RNA was eluted in 40 μL of RNase-free water and stored at -80°C.

[0439] Small RNA-seq 100ng of total RNA or 5μL of total RNA (for samples with a concentration <20ng / μL) were used for the QIAseq® miRNA Library Kit (Qiagen, Venlo, The Netherlands) to block previously reported highly abundant miRNAs (miR-16-5p, miR-486-5p, miR-451a (Roberts BS, Hardigan AA, Kirby MK, et al. Blocking of targeted microRNAs from next-generation sequencing libraries. Nucleic Acids Res. 2015;43(21):e145.doi:10.1093 / nar / gkv724, Juzenas S, Lindqvist CM, Ito G, et al. Depletion of erythropoietic miR-486-5p and miR-451a improved detectability of rare microRNAs in peripheral blood-derived small RNA sequencing libraries. NAR Genom Bioinform. 2020;2(1):lqaa008. Published 2020 Feb 12. doi:10.1093 / nargab / lqaa008). cDNA was amplified using primers that allow unique double indexing of the library (data not shown) and PCR products were purified using Mag-Bind TotalPure NGS beads (Omega Bio-Tek, Norcross, USA). PCR products after 18 cycles of amplification were assessed for size and uniformity using a Quantitative DNA kit on a Fragment Analyzer (Agilent, Santa Clara, USA).The concentration of PCR products was determined by Quant-iT dsDNA Assay-Kit (ThermoFisher Scientific, Waltham, USA), and equimolar library pools with up to 96 samples were prepared and sequenced on a NextSeq 500 (Illumina, San Diego, California) at a final pooled library concentration of 2.7 pM. A custom index 2 sequencing primer with the sequence 5'-GATCGTCGGACTGTAGAACTCTGAACGTGT-3' (SEQ ID NO: 45) was used.

[0440] statistical analysis Unpenalized, univariate and multivariate Cox models for survival regression were fitted in Python using the package scikit-survival (version 0.15.1, (Polsterl, S. (2020) scikit-survival: A Library for Time-to-Event Analysis Built on Top of scikit-learn. Journal of Machine Learning Research 21, 1-6)) and in Lifelines (version 0.26.0, (Davidson-Pilon, C. et al. (2021) CamDavidsonPilon / Lifeline:0.26.0) using the CoxPHSurvivalAnalysis and CoxPHFitter classes, respectively, with default parameter settings. To overcome the p>>n problem in modeling survival in high-dimensional data, Witten and Tibshirani have proposed a number of methods, including discrete feature selection using univariate and stepwise selection (Witten, D. M., and Tibshirani, R. (2010) Survival These are implemented in the package scikit-learn (version 0.24.2, (Pedregosa, F., et al. (2012). Scikit-learn: Machine Learning in Python. Arxiv)) and in the SelectFpr (selects miRNA features for which a Cox proportional hazards model can be fitted with p<0.05) and SequentialFeatureSelector (sequentially adds single miRNA features to a multivariate Cox proportional hazards model, up to a certain maximum number of features, based on the best improvement in the cross-validated concordance index). Using the Scikit-Learn pipeline, we combined feature selection and training steps to create a survival model and perform inference on new data. Models were trained using the Random Survival Forest model from the scikit-survival package with parameter settings (n_estimators=1000, min_samples_split=10, min_samples_leaf=15, max_features="sqrt"). Feature importance from the Random Forest model was scored by estimating the decline in model concordance when the association between survival and each feature was removed in turn (via random shuffling) using a permutation-based method from package ELI5 (version 0.11.0).Patients were stratified into high / low risk groups by the median risk score of the training data based on cut-point definitions of similar prognostic gene expression signatures previously reported (Cho, JY et al. (2011). Gene Expression Signature-Based Prognostic Risk Score in Gastric Cancer. Clin Cancer Res 17, 1850-1857; Hu,Z. et al.(2010).Serum MicroRNA Signatures Identified in a Genome-Wide Serum MicroRNA Expression Profiling predict Survival of Non-Small-Cell Lung Cancer. J Clin Oncol 28, 1721-1726; Yu, S.-L. et al. (2008) MicroRNA Signature Predicts Survival and Relapse in Lung Cancer. Cancer Cell 13, 48-57). The prognostic value of the miRisk score was evaluated in a multivariate Cox proportional hazards model with additional clinicopathological covariates (PD-L1, ECOG, sex, age, line of treatment, substance, histology, smoking status, ANC, and ALC). Survival functions were estimated using the Kaplan-Meir method, and groups were compared with the log-rank test.

[0441] qRT-PCR method For biomarker and housekeeping miRNAs, catalog and custom miRCury LNA miRNA PCR assays were ordered from Qiagen (Venlo, The Netherlands) (Table 4). 500 ng of RNA was used for cDNA synthesis, with RNA volumes up to 6.5 μL used when the concentration was insufficient. cDNA was then diluted 1:80 and a total volume of 10 μL of reaction was set up according to the manufacturer's instructions and cycled according to the following protocol: 2 min at 95°C, 40×10 s at 95°C, 60 s at 56°C in an AB Flex 6 cycler in 384-well format. Melt curve analysis was performed from 60 to 95°C. Ct values ​​were determined and exported using QuantStudio RealTime PCR Software version 1.3. Ct values ​​of the five miRisk miRNAs were determined in triplicate for a training cohort of 95 patients. ΔCt values ​​were calculated by subtracting the average of the Ct values ​​of "housekeeping" miRNAs previously defined by NGS based on their low variance. Based on these ΔCt values, the fold change (2 ΔΔCt ) and t-test were calculated for each signature miRNA.

[0442] [Table 4]

[0443] 2.2 Results Clinical characteristics of patients The training cohort consisted of 96 patients with stage IV NSCLC who received anti-PD-1 immunotherapy alone (Table 5). 77.1% (n = 74) received pembrolizumab and 22.9% (n = 22) received nivolumab. The cohort consisted of 58.3% adenocarcinoma (n = 56), 28.1% squamous cell carcinoma (n = 27), and 13.5% other NSCLC (n = 13) (including NSCLC, NOS, and large cell neuroendocrine lung cancer). 62.5% of patients were male and 38.5% were female. 91.7% of patients were former or current smokers. 49% of patients received first-line treatment and 47.9% received second-line treatment. Only 3.1% of patients received immunotherapy in the third line. 70.8% had a PD-L1 TPS ≥ 50%, 20.8% had 1-49% and 8.3% had < 1%. 36.5% were ECOG 0, 58.3% were ECOG 1 and 5.2% were ECOG 2.

[0444] A cohort of 84 additional patients with similar characteristics served as an independent validation cohort (see Table 5 below). Of this cohort, 52.4% of patients received pembrolizumab and 47.6% nivolumab; 25% received first-line, 51.2% second-line, 15.5% third-line, and 8.4% fourth-line or higher treatment; 59.5% had adenocarcinoma, 31.0% squamous cell carcinoma, and 9.5% other NSCLCs; 48.8% had PD-L1 TPS ≥ 50%, 32.1% had PD-L1 TPS 1%-49%, and 19% had PD-L1 TPS ≤ 1%; 95.3% were current or former smokers; 39.3% were ECOG 0, 54.8% had ECOG 1, 4.8% had ECOG 2, and 1.2% had ECOG 3.

[0445] [Table 5]

[0446] A third cohort of 139 patients who received non-immunotherapy monotherapy served as an independent control group (Table 5). These patients received a combination of platinum doublet and pembrolizumab immunochemotherapy. This cohort consisted of 76.3% adenocarcinoma, 12.9% squamous cell carcinoma, and 10.8% other NSCLCs. 89.2% were first-line and 10.8% second-line patients. 50.4% had PD-L1 TPS <1%, 27.3% had 1-49%, and 22.3% had PD-L1 TPS ≥50%. 40.3% were ECOG 0, 56.8% had ECOG 1, 2.2% had ECOG 2, and 0.7% had ECOG 3. 91.4% were former or current smokers.

[0447] A fourth independent cohort of 19 patients with stage IV NSCLC was included and served as an additional validation cohort.

[0448] Development of a miRNA-based risk model for overall survival (OS) under immunotherapy Using miRNA expression from a training cohort of patients (n=96), we developed a model to predict OS in stage IV NSCLC patients receiving single-agent immunotherapy with either pembrolizumab or nivolumab. A computational pipeline based on that described by Shukla et al. was created to perform initial filtering of features based on Cox univariate association with survival, followed by stepwise multivariate Cox regression to generate multiple miRNA signatures (Shukla, S. et al. (2016) Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. J Natl Cancer I 109, djw200).

[0449] More specifically, miRNA features capable of fitting a statistically significant (p<0.05) univariate Cox proportional hazards model were first selected, resulting in a shortlist of 44 miRNAs (see Table 1 above in Example 1) selected from a total of 600 miRNAs. Next, forward sequential feature selection was performed to build multivariate Cox models incorporating an increasing number of miRNA expression data. To select a small subset of features suitable for alternative low-throughput quantification platforms (e.g., qRT-PCR) and to avoid overfitting of the model, a cross-validation grid search (testing models with 3-10 features) was performed to identify a subset of 5 features that yielded optimal model performance. Finally, a Cox proportional hazards model was fitted to the entire training dataset using the five selected miRNA signatures to calculate the following risk score: miRisk=(log(miR-2115-3p RPM+1)×1.870)+(log(miR-218-5p RPM+1)×0.907)+(log(miR-224-5p RPM+1)×0.495)+(log(miR-4676-3p RPM+1)×1.309)+(log(miR-6503-5p RPM+1)×1.159).

[0450] The nucleotide sequences of miR-2115-3p, miR-218-5p, miR-224-5p, miR-4676-3p, and miR-6503-5p are shown in the attached sequence listing as SEQ ID NOs: 1, 39, 13, 7, and 34, respectively.

[0451] A risk score was calculated for all 96 patients in the training cohort (see Table 5 above), and patients were classified into low-risk and high-risk groups based on the median risk score threshold. Specifically, a miRisk score threshold = -0.13906398900641143 was calculated to stratify patients into high-risk or low-risk (high risk = miRisk > -0.13906398900641143). Patients in the low-risk group survived significantly longer than patients in the high-risk group (hazard ratio 3.98, 95% confidence interval 2.29-4.54; P = 1.560x10 -7 ) (Fig. 4a). To test the generalizable performance to new data, miRisk score analysis was performed on 84 patients from the validation cohort (Table 5). It was shown that patients in the low-risk group survived significantly longer than those in the high-risk group (hazard ratio 2.22, 95% confidence interval 1.24-3.95, P = 0.00902) (Fig. 4b).

[0452] Nonlinear models promise to capture more complex relationships between covariates and outcomes of interest (in our case miRNAs and response to immunotherapy). To investigate whether such models could lead to improved predictive performance, a random forest classifier was trained and evaluated on the dataset (Polsterl, 2020, supra). A random forest model was fitted to all 600 miRNA expression features in the training cohort without prior feature selection. A highly significant difference in overall survival was observed between low- and high-risk groups in the training cohort (Figure 5a). The random forest model shows a general performance in the validation cohort, predicting a significantly higher survival rate for low-risk patients compared to high-risk patients (hazard ratio 1.97, 95% confidence interval 1.14-3.41, P=0.0025) (Figure 5b). Finally, permutation-based feature importance was used to identify the most informative miRNA features used by the random forest classifier. Three-fifths of the miRisk miRNAs were observed among the most important features used in the random forest model, including miR-2115-3p, the miRisk model feature with the highest weighting (Table 6).

[0453] [Table 6]

[0454] Four of the five miRNAs contributing to the miRisk score are observed to be significantly elevated in high-risk patients (Fig. 6a-e). Only miR-218-5p is slightly elevated in high-risk patients, but this difference was not statistically significant (Fig. 6b). To technically validate our findings using orthogonal methods, the miRNA expression profile of 95 patients from the training cohort was re-measured using qRT-PCR. qPCR analysis reproduced the NGS results for all five miRNAs, with the same direction of change and similar degree of significance (Fig. 6f-j).

[0455] In summary, two distinct models were trained on our dataset and convergence to a subset of informative miRNA features was observed. Feature quantification was technically validated by showing consistency between measurements from both NGS and qRT-PCR. Given the high hazard ratios between risk groups predicted by the miRisk Cox-based model and its ease of interpretation, it was selected for further investigation.

[0456] The miRisk score is a predictor, not a prognostic To identify the potential predictive and prognostic significance of the miRisk score, we investigated the model's performance in two further distinct control patient cohorts of patients undergoing non-ICI monotherapy. Stratification of 139 patients from the immunochemotherapy validation cohort (Table 5) revealed no significant difference in survival between low-risk and high-risk groups (hazard ratio 1.357, 95% confidence interval 0.72 to 2.572, p = 0.366) (Figure 4c). This is consistent with previous findings that immunotherapy biomarkers (tumor PD-L1) do not predict survival benefit when immunotherapy is added to chemotherapy alone (Gandhi, L. et al. (2018).Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. New Engl J Med 378, 2078-2092). The model was validated in a further independent control cohort of 19 stage IV NSCLC patients recruited in Grosshansdorf, Germany, who chose to undergo watchful waiting without treatment. When the miRisk score was calculated, no significant difference in overall survival was observed between risk groups (Figure 7). Again, this provides evidence against the prognostic model and in support of a specific prediction of immunotherapy response.

[0457] Evaluation of the miRisk score in clinical settings Univariate and multivariate Cox regressions were performed within the immune monotherapy validation cohort to explore the association of miRisk score with other clinical covariates with respect to overall survival (Table 7). In addition to miRisk score, clinicopathological covariates associated with immunotherapy response were included in the Cox model. In univariate analysis, a significant association was observed between ECOG (hazard ratio 2.90, 95% confidence interval 1.47-5.73, P = 0.00) and miRisk score (hazard ratio 2.23, 95% confidence interval 1.2-4.15, P = 0.01). A non-significant association was observed between tumor PD-L1 < 50% and survival in the immune therapy validation cohort, with a predicted trend toward increased risk with lower PD-L1 (hazard ratio 1.78, 95% confidence interval 0.97-3.28, P = 0.06) (Table 7). In univariate analysis, a non-significant protective effect was observed for both low ANC and high ALC (Table 7), which is in line with published predictive signatures derived from peripheral blood counts (Tanizaki, J. et al. (2018). Peripheral blood biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.Journal of Thoracic Oncology:Official Publication of the International Association for the Study of Lung Cancer 13, 97-105). This effect was attenuated when adjusting for other covariates in multivariate analysis. In multivariate Cox regression, both ECOG and miRisk scores remained significant independent predictors of overall survival (Table 7).

[0458] [Table 7]

[0459] miRisk score is superior to PD-L1 histology as a predictive biomarker Tumor PD-L1 expression is currently the only approved companion diagnostic biomarker to predict immunotherapy response in NSCLC and is recognized in current ASCO and ESMO guidelines when selecting treatment options. Patients in both cohorts were stratified based on PD-L1 tumor staining levels (>50%) and survival was assessed by Kaplan-Meier analysis (Fig. 4d-f). There is a trend towards longer overall survival in high PD-L1 patients, but this did not reach significance in either cohort, in contrast to the miRisk score, which was observed to be a significant predictor. This is in line with a recent meta-analysis that found that PD-L1 predicted immunotherapy response in only about 30% of patients with various tumor types (Davis,AAand Patel,VG(2019).The role of PD-L1 expression as a predictive biomarker:a analysis of all US Food and Drug Administration(FDA)approvals of immune checkpoint inhibitors. J Immunother Cancer 7,278.).

[0460] The miR-score model was retrained using tumor PD-L1 in addition to the five previously identified signature miRNAs. Adding tumor PD-L1 expression levels did not significantly improve the predictive performance (Figure 8). This clearly indicates that the approach presented here enables rapid and accurate clinical response prediction and life prognosis in cancer diseases (independent of PD-L1 expression).

[0461] 3. Example 3: 3.1 Method The study included a total of 155 prospectively enrolled patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) ≥ 50%. Blood samples from these patients were collected from the University of Heidelberg (S-296 / 2016, S-089 / 2019, S-916 / 2019) and Grosshansdorf Hospital (AZ) in accordance with the relevant regulations. Blood samples were provided by the Lungenbiobank Heidelberg and Biobank Nord with approval from the local ethical committee (Heidelberg, 12-238, AZ 19-286). Processing of blood samples and generation of small RNA expression profiles by small RNA sequencing have been described in detail above. All anonymized small RNA sequencing data have been deposited in the European Nucleotide Archive (ENA) under the accession number PRJEB50502. Survival analyses were performed in Python (3.8.8) using the packages Scikit-Survival (version 0.15.1) and Lifelines (version 0.26.0). Kaplan-Meier analyses were performed with Graphpad Prism (GraphpadPrism, version 9.3.1).

[0462] 3.2 Results The study included training (n=68) and validation (n=56) cohorts of 124 patients with stage IV NSCLC undergoing immunotherapy (IO-), divided according to the time point of sample collection, as well as a control cohort (n=31) treated with immunochemotherapy (ICT) (Table 8). These three cohorts show broadly similar clinicopathological characteristics.

[0463] [Table 8]

[0464] A significant increase in overall survival was observed in patients with low miRisk scores in the training cohort (hazard ratio 3.65, 95% CI 1.84-7.24; P<0.001) (data not shown), which was also confirmed in the validation cohort (hazard ratio 5.24, 95% CI 2.17-12.66; P<0.001) (Fig. 10a). In contrast, miRisk scores were not associated with overall survival (OS) in patients in the chemoimmunotherapy (ICT) control cohort (hazard ratio 1.40, 95% CI 0.21-9.28; P=0.753) (Fig. 10b), which is consistent with previous reports that IO-specific biomarkers cannot predict response to ICT.

[0465] To investigate the utility of the miRisk score as a complementary diagnostic for treatment decisions between immunotherapy (IO) and immunochemotherapy (ICT), we combined validation and control cohorts to investigate the interaction between overall survival (OS) and treatment.

[0466] In patients with low miRisk, there was no difference in OS between IO and ICT (hazard ratio 1.22, 95% CI 0.12-12.25, p=0.849) (Fig. 10c). In contrast, in patients with high miRisk, a significant improvement in OS was observed in patients receiving ICT compared with IO (hazard ratio 0.35, 95% CI 0.15-0.82, P=0.018) (Fig. 10d). The interaction between treatment and miRisk score in the multivariate Cox proportional hazards model was significant (P=0.036), suggesting that miRisk score was associated with the efficacy of IO. These results suggest that IL-16 is both prognostic and predictive of IL-16 (data not shown).

[0467] Finally, a multivariate Cox proportional hazards model was used to investigate the performance of the miRisk score when adjusting for other relevant clinicopathological covariates, which showed that the miRisk score showed a stronger association with OS in IO-treated patients (hazard ratio 4.45, 95% confidence interval 1.58-12.49, P = 0.004) than PD-L1 TPS, tumor histology, and ECOG performance status (Table 9).

[0468] [Table 9]

[0469] In particular, fitting a multivariate Cox proportional hazards model to the training cohort using the five previously identified miRNAs as input features led to a modified risk score with adjusted weights; miRisk=(ln(miR-2115-3p RPM+1)×2.190467)+(ln(miR-218-5p RPM+1)×0.303095)+(ln(miR-224-5p RPM+1)×0.598415)+(ln(miR-4676-3p RPM+1)×1.101122)+(ln(miR-6503-5p RPM+1)×0.958823).

[0470] The nucleotide sequences of miR-2115-3p, miR-218-5p, miR-224-5p, miR-4676-3p, and miR-6503-5p are shown in the attached sequence listing as SEQ ID NOs: 1, 39, 13, 7, and 34, respectively.

[0471] In particular, a miRisk cutoff score / threshold of -0.07250442496171916 was calculated, allowing for stratification of patients as likely to benefit from immunochemotherapy (miRisk score > -0.07250442496171916, rounded to -0.073) or for stratification of patients as likely to benefit from immunochemotherapy or immunotherapy (miRisk score ≦ -0.07250442496171916, rounded to -0.073).

[0472] In summary, the above results indicate that the cutoff / threshold value of the miRisk score can identify the PD-L1 high group, i.e., stage IV NSCLC patients who would benefit from the addition of chemotherapy to immunotherapy. The cut-off scores / thresholds of miRisk allow to identify a group of high-risk patients who are more likely to benefit from treatment with ICT as opposed to IO. Thus, the miRisk cut-offs / thresholds support treatment decisions as a complementary diagnostic.

Claims

1. A method for predicting a response to lung cancer immunotherapy in a patient suffering from lung cancer, comprising: determining the level of at least one miRNA in a blood sample from a patient suffering from lung cancer; The at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80% sequence identity thereto. method

2. The at least one miRNA is (i) the group consisting of SEQ ID NO: 1 to SEQ ID NO: 8, fragments thereof, and sequences having at least 80% sequence identity thereto; and / or (ii) the group consisting of SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, SEQ ID NO:39, fragments thereof, and sequences having at least 80% sequence identity thereto; The method of claim 1, having a nucleotide sequence selected from:

3. the level of the at least one miRNA is compared to a reference level of the at least one miRNA; The reference level is a level of at least one miRNA empirically determined by measuring multiple reference blood samples from subjects suffering from lung cancer that is non-responsive to the lung cancer immunotherapy; and a level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 to SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39 to SEQ ID NO:42, SEQ ID NO:44, fragments thereof, and sequences having at least 80% sequence identity thereto, lower than the reference level indicates that the patient will respond to the lung cancer immunotherapy; or The at least one miR having a nucleotide sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:43, fragments thereof, and sequences having at least 80% sequence identity thereto, which is higher than the reference level. The level of NA indicates that the patient will respond to the lung cancer immunotherapy. The method according to claim 1 or claim 2.

4. The level of the at least one miRNA is compared to an empirically determined cut-off score that allows classifying the patient as a patient who will respond to lung cancer immunotherapy or a patient who will not respond to lung cancer immunotherapy; The cut-off score is determined by a weighted sum of one or more miRNAs selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 34, SEQ ID NO: 39, fragments thereof, and sequences having at least 80% sequence identity thereto; The method of claim 1.

5. 2. The method of claim 1, wherein the lung cancer immunotherapy involves administration of at least one immune checkpoint inhibitor.

6. 6. The method of claim 5, wherein the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and endogenous checkpoint blockade.

7. 2. The method of claim 1, wherein the lung cancer is non-small cell lung cancer (NSCLC).

8. A method for providing a prognosis for a patient suffering from lung cancer who is a target of immunotherapy, comprising: determining the level of at least one miRNA in a blood sample from a patient suffering from lung cancer; The at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80% sequence identity thereto. method.

9. The at least one miRNA is (i) the group consisting of SEQ ID NO: 1 to SEQ ID NO: 8, fragments thereof, and sequences having at least 80% sequence identity thereto; and / or (ii) the group consisting of SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:34, SEQ ID NO:39, fragments thereof, and sequences having at least 80% sequence identity thereto; The method of claim 8, having a nucleotide sequence selected from:

10. the level of the at least one miRNA is compared to a reference level of the at least one miRNA; the reference level is a level of the at least one miRNA empirically determined by measuring a number of reference blood samples from subjects suffering from lung cancer with a known poor life prognosis; and a level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28 to SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39 to SEQ ID NO:42, SEQ ID NO:44, fragments thereof, and sequences having at least 80% sequence identity thereto, lower than the reference level indicates that the patient has a favorable prognosis for life; or A level of the at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:43, fragments thereof, and sequences having at least 80% sequence identity thereto, higher than the reference level indicates that the patient has a favorable prognosis. The method according to claim 8 or claim 9.

11. The level of the at least one miRNA is compared to an empirically determined cut-off score that allows classifying the patient as having a good or bad life prognosis; The cut-off score is determined by a weighted sum of one or more miRNAs selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 34, SEQ ID NO: 39, fragments thereof, and sequences having at least 80% sequence identity thereto; The method according to claim 8.

12. 12. The method of claim 11, wherein the good life prognosis is associated with a high possibility / probability of surviving for a certain period of time, or the poor life prognosis is associated with a low possibility / probability of surviving for a certain period of time.

13. The method according to claim 8 , wherein the patient is scheduled to receive lung cancer immunotherapy.

14. 14. The method of claim 13, wherein the lung cancer immunotherapy involves administration of at least one immune checkpoint inhibitor.

15. 15. The method of claim 14, wherein the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and endogenous checkpoint blockade.

16. 9. The method of claim 8, wherein the cancer is non-small cell lung cancer (NSCLC).

17. A method for determining whether to treat a patient suffering from lung cancer with immunotherapy, comprising: (i) identifying the patient as a patient who responds to lung cancer immunotherapy by carrying out the method of claim 1, or identifying the patient as a patient who has a good life prognosis under immunotherapy by carrying out the method of claim 8; and (ii) assigning the patient to a lung cancer immunotherapy (as described above). A method comprising:

18. 18. The method of claim 17, wherein the lung cancer immunotherapy involves administration of at least one immune checkpoint inhibitor.

19. 19. The method of claim 18, wherein the at least one immune checkpoint inhibitor is selected from the group consisting of inhibitors targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD73, and endogenous checkpoint blockade.

20. Use of at least one miRNA for predicting a response to lung cancer immunotherapy in a patient suffering from lung cancer, comprising: The at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80% sequence identity thereto; use.

21. Use of at least one miRNA for providing a prognosis for a patient suffering from lung cancer who is a candidate for immunotherapy, comprising: The at least one miRNA is a nucleic acid selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80% sequence identity thereto. having a nucleotide sequence, use.

22. Use of at least one miRNA for determining whether to treat a patient suffering from lung cancer with immunotherapy, comprising: The at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80% sequence identity thereto; use

23. Use of a kit for predicting a response of a patient suffering from lung cancer to lung cancer immunotherapy, for providing a prognosis for a patient suffering from lung cancer who is a target of immunotherapy, or for determining whether to treat a patient suffering from lung cancer with immunotherapy, comprising: The kit comprises a means for determining the level of at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 44, fragments thereof, and sequences having at least 80% sequence identity thereto; use.

24. 1. A method for selecting a patient suffering from cancer who will benefit from immunochemotherapy or immunotherapy, comprising: determining the level of at least one miRNA in a blood sample from a patient suffering from cancer; wherein the at least one miRNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 (miR-2115-3p), SEQ ID NO: 39 (miR-218-5p), SEQ ID NO: 13 (miR-224-5p), SEQ ID NO: 7 (miR-4676-3p), SEQ ID NO: 34 (miR-6503-5p), fragments thereof, and sequences having at least 80% sequence identity thereto; method.

25. 25. The method of claim 24, wherein the lung cancer is non-small cell lung cancer (NSCLC).

26. The level of the at least one miRNA is compared to a (miRisk) cutoff score; The method of claim 24 or claim 25, wherein a level of at least one miRNA higher than the (miRisk) cut-off score indicates that the patient will benefit from immunochemotherapy, or a level of at least one miRNA below the (miRisk) cut-off score indicates that the patient will benefit from immunochemotherapy or immunotherapy.

27. 25. The method of claim 24, wherein the method further comprises determining a (miRisk) score by aggregating weighted levels of at least two, at least three, at least four, or five miRNAs having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 (miR-2115-3p), SEQ ID NO:39 (miR-218-5p), SEQ ID NO:13 (miR-224-5p), SEQ ID NO:7 (miR-4676-3p), SEQ ID NO:34 (miR-6503-5p), fragments thereof, and sequences having at least 80% sequence identity thereto.

28. 1. A method for determining whether to treat a patient suffering from cancer with immunochemotherapy or immunotherapy, comprising: (i) the administration of a therapeutic agent from immunochemotherapy or immunotherapy by carrying out the method according to claim 24; Identifying the patient as one who will benefit; and (ii) allocating said patient to said treatment; The method includes:

29. 1. Use of a kit for selecting a patient suffering from lung cancer who will benefit from immunochemotherapy or immunotherapy, comprising: The kit comprises means for determining the level of at least one miRNA having a nucleotide sequence selected from the group consisting of SEQ ID NO:1 (miR-2115-3p), SEQ ID NO:39 (miR-218-5p), SEQ ID NO:13 (miR-224-5p), SEQ ID NO:7 (miR-4676-3p), SEQ ID NO:34 (miR-6503-5p), fragments thereof, and sequences having at least 80% sequence identity thereto, in a blood sample of the patient suffering from lung cancer; Optionally, the patient has a PD-L1 Tumor Proportion Score (TPS) of ≧50%. use.